<SEC-DOCUMENT>0001144204-18-051362.txt : 20180928
<SEC-HEADER>0001144204-18-051362.hdr.sgml : 20180928
<ACCEPTANCE-DATETIME>20180928082442
ACCESSION NUMBER:		0001144204-18-051362
CONFORMED SUBMISSION TYPE:	SUPPL
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20180928
DATE AS OF CHANGE:		20180928
EFFECTIVENESS DATE:		20180928

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SUPPL
		SEC ACT:		
		SEC FILE NUMBER:	333-224432
		FILM NUMBER:		181092544

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>SUPPL
<SEQUENCE>1
<FILENAME>tv503751_suppl.htm
<DESCRIPTION>SUPPL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Filed pursuant to General Instruction II.L of Form F-10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>File No. 333-224432</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To Base Shelf Prospectus dated May 4, 2018)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv503751_logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>US$26,910,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into a purchase agreement
(the &ldquo;<B>Purchase Agreement</B>&rdquo;) dated September 28, 2018 with Lincoln Park Capital Fund, LLC (&ldquo;<B>Lincoln Park</B>&rdquo;),
relating to our common shares (&ldquo;<B>Common Shares</B>&rdquo;). In accordance with the terms of the Purchase Agreement, we
may offer and sell our (the &ldquo;<B>Offering</B>&rdquo;) Common Shares to Lincoln Park up to an aggregate Offering amount of
US$26,000,000 during the 30-month term of the Purchase Agreement. See &ldquo;<I>Plan of Distribution</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares offered to Lincoln Park
hereunder include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">248,762 of our Common Shares that Lincoln Park is purchasing for gross proceeds of US$1,000,000
as an initial purchase, at a purchase price of US$4.0199 per Common Share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">up to US$25,000,000 of our Common Shares that may be sold from time to time after the initial purchase,
at our sole discretion, to Lincoln Park over the 30 month period which commenced on September 28, 2018 in accordance with the Purchase
Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">110,754 Common Shares to be issued to Lincoln Park as initial commitment shares (the &ldquo;<B>Initial
Commitment Shares</B>&rdquo;) as consideration for the entering into of the Purchase Agreement on September 28, 2018, valued at
US$4.1082 per Common Share for a total aggregate value of app US$455,000 issued under this Prospectus Supplement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">up to 110,754 additional Common Shares, valued at US$4.1082 per Common Share, that we may issue
to Lincoln Park on a <I>pro rata</I> basis as additional commitment shares (the &ldquo;<B>Additional Commitment Shares</B>&rdquo;),
upon each purchase by Lincoln Park under the Purchase Agreement (including the initial purchase of US$1,000,000 of Common Shares).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus Supplement also qualifies
for distribution the resale of these Common Shares by Lincoln Park to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Shares are listed on the Nasdaq
Capital Market (&ldquo;<B>NASDAQ</B>&rdquo;) under the symbol &ldquo;ONCY&rdquo; and on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;)
under the symbol &ldquo;ONC&rdquo;. On September 27, 2018, the last reported sale price of our Common Shares was US$4.0199 per
Common Share on NASDAQ and C$5.21 per Common Share on the TSX. None of our Common Shares issued pursuant to the Purchase Agreement
will be offered for sale or sold by us or Lincoln Park on the TSX or to purchasers in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lincoln Park will not engage in any
transactions that stabilize the price of our Common Shares. No underwriter or dealer involved in the distribution, no affiliate
of such an underwriter or dealer and no person or company acting jointly or in concert with such an underwriter or dealer has over-allotted,
or will over-allot, securities in connection with the distribution or effect any other transactions that are intended to stabilize
or maintain the market price of the securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in the Common Shares is
speculative and bears certain risks. See &ldquo;Risk Factors&rdquo; on beginning on page S-9 in this Prospectus Supplement and
on page 6 of the accompanying Prospectus. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Offering is made by a Canadian issuer
that is permitted, under a multijurisdictional disclosure system adopted by the United States and Canada (&ldquo;MJDS&rdquo;),
to prepare this Prospectus Supplement and the Prospectus in accordance with Canadian disclosure requirements. Prospective investors
in the United States should be aware that such requirements are different from those of the United States. Financial statements
included or incorporated by reference in the Prospectus have been prepared in accordance with International Financial Reporting
Standards (&ldquo;IFRS&rdquo;) as issued by the International Accounting Standards Board (&ldquo;IASB&rdquo;) and may not be comparable
to financial statements of United States companies. Such financial statements are subject to Canadian generally accepted auditing
standards and auditor independence standards, in addition to the standards of the Public Company Accounting Oversight Board (United
States) and the United States Securities and Exchange Commission (&ldquo;SEC&rdquo;) independence standards.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective investors should be aware
that the acquisition of the Common Shares described herein may have tax consequences both in the United States and in Canada. Such
consequences for investors who are resident in, or citizens of, the United States may not be described fully herein. This Prospectus
Supplement and the Prospectus may not describe these tax consequences fully. You should read the tax discussion under the heading
 &ldquo;<I>Material U.S. Federal Income Tax Considerations</I>&rdquo; in this Prospectus Supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The enforcement by investors of civil
liabilities under the United States federal securities laws may be affected adversely by the fact that the Corporation is incorporated
under the laws of Alberta, Canada, that the majority of its officers and directors are residents of Canada, that many of the experts
named in this Prospectus Supplement and the Prospectus are not residents of the United States, and that a substantial portion of
the assets of the Corporation and said persons are located outside the United States. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano, William G. Rice and
Bernd R. Seizinger are directors of the Corporation who reside outside of Canada. Messrs. Pisano, Rice and Seizinger have appointed
the Corporation, at its principal place of business, as agent for service of process. Purchasers are advised that it may not be
possible for investors to enforce judgments obtained in Canada against any person that resides outside of Canada, even if the party
has appointed an agent for service of process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE SEC NOR ANY STATE OR CANADIAN
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE SECURITIES OFFERED HEREBY OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT OR
THE ACCOMPANYING PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial information of the Corporation
incorporated by reference in the Prospectus is presented in Canadian dollars. Unless otherwise noted herein, all references to
 &ldquo;US$&rdquo;, &ldquo;United States dollars&rdquo; or &ldquo;US dollars&rdquo; are to United States dollars and all references
to &ldquo;C$&rdquo; or &ldquo;$&rdquo;, are to Canadian dollars. See &ldquo;<I>Exchange Rate</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N 1X7. Our registered office is located at 4000,
421 - 7<SUP>th</SUP> Avenue S.W., Calgary, Alberta, T2P 4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>The date
of this Prospectus Supplement is September 28, 2018.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal"><U>Prospectus
Supplement</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 89%"><A HREF="#sa_001">IMPORTANT NOTICE ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><A HREF="#sa_001">S-4</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_002">FORWARD-LOOKING STATEMENTS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_002">S-4</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_003">DOCUMENTS INCORPORATED BY REFERENCE</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_003">S-6</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_004">DOCUMENTS FILED AS PART OF THE REGISTRATION STATEMENT</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_004">S-7</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_005">CURRENCY AND EXCHANGE RATE INFORMATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_005">S-7</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_006">OFFERING SUMMARY</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_006">S-8</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_007">RISK FACTORS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_007">S-9</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_008">THE CORPORATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_008">S-10</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_009">RECENT DEVELOPMENTS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_009">S-11</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_010">BUSINESS OF THE CORPORATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_010">S-13</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_011">USE OF PROCEEDS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_011">S-18</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_012">CONSOLIDATED CAPITALIZATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_012">S-18</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_013">TRADING PRICE AND VOLUME</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_013">S-18</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_014">PRIOR SALES</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_014">S-19</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_015">PLAN OF DISTRIBUTION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_015">S-20</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_016">CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_016">S-22</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_017">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_017">S-24</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_018">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_018">S-31</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#sa_019">LEGAL MATTERS AND INTEREST OF EXPERTS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_019">S-32</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#sa_020">AGENT FOR SERVICE OF PROCESS</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#sa_020">S-32</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal"><U>Base
Shelf Prospectus dated May 4, 2018</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">ABOUT
    THIS PROSPECTUS AND OTHER MATTERS</A></FONT></TD>
    <TD STYLE="width: 10%; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">4</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">FORWARD-LOOKING
    STATEMENTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">4</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">6</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">DOCUMENTS
    INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">6</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">DOCUMENTS
    FILED AS PART OF THE REGISTRATION STATEMENT</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">7</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">ADDITIONAL
    INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">THE
    CORPORATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">BUSINESS
    OF THE CORPORATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">CONSOLIDATED
    CAPITALIZATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">DESCRIPTION
    OF SHARE CAPITAL</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">DESCRIPTION
    OF SUBSCRIPTION RECEIPTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">10</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">11</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">12</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015">PLAN
    OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015">12</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016">PRIOR
    SALES</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016">13</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017">TRADING
    PRICE AND VOLUME</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017">13</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018">CERTAIN
    INCOME TAX CONSIDERATIONS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019">LEGAL
    MATTERS AND INTERESTS OF EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020">AUDITORS,
    TRANSFER AGENT AND REGISTRAR</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">AGENT
    FOR SERVICE OF PROCESS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022">ENFORCEABILITY
    OF CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022">14</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_001"></A>IMPORTANT NOTICE
ABOUT INFORMATION IN THIS PROSPECTUS SUPPLEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is in two parts. The first
part is this Prospectus Supplement, which describes the specific terms of the Offering and Common Shares and the method of distribution
of the Common Shares and also supplements and updates information regarding Oncolytics Biotech Inc. contained and incorporated
by reference in the Prospectus. The second part is the accompanying Prospectus, which gives more general information, some of which
may not apply to the Common Shares. Both documents contain important information you should consider when making your investment
decision. If the description of the Common Shares varies between this Prospectus Supplement and the accompanying Prospectus, investors
should rely on the information in this Prospectus Supplement. This Prospectus Supplement is deemed to be incorporated by reference
into the Prospectus solely for the purpose of the Offering. If information in this Prospectus Supplement is inconsistent with the
Prospectus or the information incorporated by reference in the Prospectus, you should rely on this Prospectus Supplement. You should
read both this Prospectus Supplement and the accompanying Prospectus, together with the additional information about us to which
we refer you in the section of this Prospectus Supplement entitled &ldquo;<I>Where You Can Find Additional Information</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in this Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus. The Corporation
and the Underwriter have not authorized anyone to provide you with different information. If anyone provides you with any different
or inconsistent information, you should not rely on it. The Corporation is offering the Common Shares only in jurisdictions where
such offers are permitted by law.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should assume that the information
contained in this Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus is accurate
only as of their respective dates, regardless of the time of delivery of this Prospectus Supplement and the accompanying Prospectus.
</B>Our business, financial condition, results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market data and certain industry forecasts
used in this Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus were obtained
from market research, publicly available information and industry publications. We believe that these sources are generally reliable,
but the accuracy and completeness of this information is not guaranteed. We have not independently verified such information, and
we do not make any representation as to the accuracy of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus Supplement, &ldquo;<B>Oncolytics</B>,&rdquo;
the &ldquo;<B>Corporation</B>,&rdquo; &ldquo;<B>we</B>,&rdquo; &ldquo;<B>us</B>,&rdquo; and &ldquo;our&rdquo; refer to Oncolytics
Biotech Inc. and its subsidiaries.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_002"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus Supplement, the Prospectus
and the documents incorporated by reference in the Prospectus contain certain statements relating to future events or the Corporation&rsquo;s
future performance which constitute forward-looking statements. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results, performance or achievements of the Corporation, or industry
results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking
statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates
and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies;
the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of
regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry
and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future
performance. Forward-looking statements generally, but not always, are identified by the words &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
 &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects&rdquo;, &ldquo;potential&rdquo;, &ldquo;possible&rdquo;
and similar expressions, or that events or conditions &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;could&rdquo; or &ldquo;should&rdquo;
occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this
Prospectus Supplement, the Prospectus and the documents incorporated by reference in the Prospectus are subject to various risks
and uncertainties, most of which are difficult to predict and generally beyond the Corporation&rsquo;s control, including without
limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to all of our products, including REOLYSIN&reg; (pelareorep), being in the research
and development stage and requiring further development and testing before they can be marketed commercially;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks inherent in pharmaceutical research and development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to timing and possible delays in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to some of our clinical trials being conducted in, and subject to the laws of, foreign
countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our pharmaceutical products being subject to intense regulatory approval processes
in the United States and other foreign jurisdictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to being subject to government manufacturing and testing regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to the extremely competitive biotechnology industry and our competition with larger
companies with greater resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our reliance on patents and proprietary rights to protect our technology;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to potential product liability claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our limited manufacturing experience and reliance on third parties to commercially
manufacture our products, if and when developed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our new products not being accepted by the medical community or consumers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our technologies becoming obsolete;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our dependence on third party relationships for research and clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our license, development, supply and distribution agreement with Adlai Nortye
Biopharma Co. Ltd.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our lack of operating revenues and history of losses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to other third-party arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our ability to obtain additional financing to fund future research and development
of our products and to meet ongoing capital requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to potential increases in the cost of director and officer liability insurance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our dependence on key employees and collaborators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to Barbados law, including those relating to the enforcement of judgments obtained
in Canada or the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to the effect of changes in the law on our corporate structure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate
fluctuations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to fluctuations in interest rates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to information technology systems; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">risks related to our Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This list is not exhaustive of the factors
that may affect any of the Corporation&rsquo;s forward-looking statements. Some of the important risks and uncertainties that could
affect forward-looking statements are described further under the heading &ldquo;<I>Risk Factors</I>&rdquo; in this Prospectus
Supplement, in the Prospectus and in the Corporation&rsquo;s Annual Report (as defined below). If one or more of these risks or
uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected,
estimated or projected. Forward-looking statements in this document are not a prediction of future events or circumstances, and
those future events or circumstances may not occur. Given these uncertainties, users of the information included herein, including
investors and prospective investors, are cautioned not to place undue reliance on such forward-looking statements. Investors should
consult our quarterly and annual filings with the securities commissions or similar regulatory authorities in Canada and the SEC
for additional information on risks and uncertainties relating to forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation cautions that the foregoing
list of factors that may affect future results is not exhaustive. The forward-looking information contained in this Prospectus
Supplement, the Prospectus and the documents incorporated by reference in the Prospectus is made as of the date of such documents.
The forward-looking information contained in this Prospectus Supplement, the Prospectus and in the documents incorporated by reference
in the Prospectus is expressly qualified by this cautionary statement. The Corporation does not undertake any obligation to publicly
update or revise any forward-looking information except as required pursuant to applicable securities laws.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_003"></A>DOCUMENTS INCORPORATED
BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This Prospectus Supplement is deemed
to be incorporated by reference into the Prospectus solely for the purposes of the Offering.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information has been incorporated by
reference in the Prospectus from documents filed with securities commissions or similar authorities in Canada. </B>Copies of the
documents incorporated herein by reference may be obtained on request without charge from our Corporate Secretary at 210, 1167
Kensington Crescent N.W., Calgary, Alberta, T2N 1X7 telephone (403) 670-7377, and are available electronically under the Corporation&rsquo;s
profile on SEDAR (www.sedar.com) and on EDGAR (www.sec.gov/edgar.shtml).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents, filed with the
securities commissions or similar regulatory authorities in each of the provinces of Canada and filed with, or furnished to, the
SEC are specifically incorporated by reference into, and form an integral part of, the Prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our annual report on Form 20-F (&ldquo;<B>Annual Report</B>&rdquo;) dated March 19, 2018, for the
year ended December 31, 2017 (filed in Canada with the Canadian securities regulatory authorities in lieu of an annual information
form);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management information circular dated March 27, 2018 relating to the annual general meeting
of shareholders held on May 3, 2018;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our audited consolidated financial statements, together with the notes thereto, as at December
31, 2017 and 2016, which comprise the consolidated statements of financial position as at December 31, 2017 and 2016, and the consolidated
statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December 31, 2017 and 2016, together
with the independent auditors&rsquo; report thereon;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management&rsquo;s discussion and analysis of financial condition and results of operations
dated March 8, 2018, for the year ended December 31, 2017;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our unaudited interim consolidated financial statements, together with the notes thereto, as at
June 30, 2018 and 2017, which comprise the interim consolidated statements of financial position as at June 30, 2018 and 2017,
and the interim consolidated statements of loss and comprehensive loss, changes in equity, and cash flows for the six months ended
June 30, 2018 and 2017; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our management&rsquo;s discussion and analysis of financial condition and results of operations
dated August 2, 2018, for the six months ended June 30, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any documents of the type required by National
Instrument 44-101 - <I>Short Form Prospectus Distributions</I> to be incorporated by reference in a short form Prospectus, including
any annual information form, annual report on Form 20-F, comparative annual consolidated financial statements and the auditors&rsquo;
report thereon, comparative interim consolidated financial statements, management&rsquo;s discussion and analysis of financial
condition and results of operations, material change report (except a confidential material change report), business acquisition
report and information circular, if filed by us with the securities commissions or similar authorities in Canada after the date
of this Prospectus Supplement and prior to the date on which the Offering under this Prospectus Supplement ends, shall be deemed
to be incorporated by reference in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent that any document
or information incorporated by reference in the Prospectus is included in any report filed with or furnished to the SEC pursuant
to the United States Securities Exchange Act of 1934, as amended (the &ldquo;<B>U.S. Exchange Act</B>&rdquo;), after the date of
this Prospectus Supplement and prior to the date on which the Offering under this Prospectus Supplement ends, such document or
information shall be deemed to be incorporated by reference as an exhibit to the registration statement of which this Prospectus
Supplement and the Prospectus forms a part (in the case of documents or information deemed furnished on Form 6-K or Form 8-K, only
to the extent specifically stated therein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any statement contained in this Prospectus
Supplement, the Prospectus or in a document incorporated or deemed to be incorporated by reference in the Prospectus shall be deemed
to be modified or superseded for the purposes of this Prospectus Supplement and the Prospectus to the extent that a statement contained
herein or in any other subsequently filed document which also is, or is deemed to be, incorporated by reference in the Prospectus
or therein modifies or supersedes such statement. The modifying or superseding statement need not state that it has modified or
superseded a prior statement or include any other information set forth in the document that it modifies or supersedes. The making
of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement,
when made, constituted a misrepresentation, an untrue statement of a material fact or an omission to state a material fact that
was required to be stated or that was necessary to make a statement not misleading in light of the circumstances in which it was
made. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of
this Prospectus Supplement or the Prospectus.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_004"></A>DOCUMENTS FILED AS
PART OF THE REGISTRATION STATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents have been or will
be filed with the SEC as part of the registration statement of which this Prospectus Supplement and the Prospectus forms a part:
(i) the documents set out under the heading &ldquo;<I>Documents Incorporated by Reference</I>&rdquo; in this Prospectus Supplement
and the Prospectus; (ii) the consents of the Corporation&rsquo;s auditor and legal counsels; (iii) the powers of attorney from
the directors and certain officers of the Corporation and (iv) the Purchase Agreement described in this Prospectus Supplement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_005"></A>CURRENCY AND EXCHANGE
RATE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus Supplement and the accompanying
Prospectus, unless otherwise indicated, all dollar amounts and references to &ldquo;$&rdquo; and &ldquo;US$&rdquo; are to U.S.
dollars and references to &ldquo;C$&rdquo; are to Canadian dollars. This Prospectus Supplement and the accompanying Prospectus
and the documents incorporated by reference in the Prospectus contain translations of some Canadian dollar amounts into U.S. dollars
solely for your convenience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth, for the periods indicated, the
high, low, average and period-end rates of exchange for US$1.00, expressed in Canadian dollars, posted by the Bank of Canada:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>2017<SUP>(1)</SUP></B></P></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>2016<SUP>(2)</SUP></B></P></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>2015<SUP>(2)</SUP></B></P></TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Highest rate during the period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">C$1.3743</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">C$1.4589</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">C$1.3990</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lowest rate during the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.2128</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.2544</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.1728</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Average rate for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.2986</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.3248</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.2787</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at the end of the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.2545</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.3427</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">C$1.3840</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notes:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017
data from the Bank of Canada reflects the daily average noon rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016
and 2015 data from the Bank of Canada reflects the noon exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 27, 2018, the daily average
exchange rate posted by the Bank of Canada for conversion of U.S. dollars into Canadian dollars was US$1.00 = C$1.3045. Unless
otherwise indicated, currency translation in this Prospectus Supplement reflect the September 27, 2018 rate.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<DIV>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_006"></A>OFFERING SUMMARY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><B>Issuer:</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Oncolytics Biotech Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Offering:</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Shares having an aggregate offering
        price of US$26,910,000 over the 30-month term of the Purchase Agreement, including:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;248,762
        Common Shares that Lincoln Park is purchasing for gross proceeds of US$1,000,000 as an initial purchase under the Purchase Agreement,
        at a purchase price of US$4.0199 per Common Share;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Up
        to US$25,000,000 of Common Shares that may be sold from time to time after the initial purchase, as our sole discretion, to Lincoln
        Park over the next 30 months in accordance with the terms of the Purchase Agreement;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;110,754
        Common Shares to be issued to Lincoln Park as Initial Commitment Shares in consideration for entering the Purchase Agreement; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: -17.1pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;110,754
        Common Shares that we may issue to Lincoln Park, on a <I>pro rata</I> basis, as Additional Commitment Shares, upon each purchase
        by Lincoln Park under the Purchase Agreement (including the initial purchase of US$1,000,000).</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Common Shares Outstanding Before this Offering:</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">16,551,549 Common Shares (non-diluted)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Common Shares Outstanding Immediately Following this Offering:</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">23,245,299 Common Shares (non-diluted) after the issuance of up to 6,219,060 Common Shares, assuming a sales price of US$4.0199 per Common Share, which was the closing price of the Common Shares on NASDAQ on September 27, 2018, for the remaining US25,000,000 that may be sold from time to time after the initial purchase of 248,762 Common Shares for proceeds of US$1,000,000 and after the issuance of 110,754 Initial Commitment Shares and 110,754 Additional Commitment Shares. The actual number of Common Shares issued and outstanding will vary depending on the actual sales prices and aggregate dollar amount sold under the Offering.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Use of Proceeds:</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">We intend to use the net proceeds from the Offering, if any, for the advancement of the Corporation&rsquo;s clinical development program, related support costs and general corporate and administrative expenses. The amounts actually expended for the purposes described above may vary significantly depending upon a number of factors, including those listed under the heading &ldquo;Risk Factors&rdquo; in this Prospectus Supplement. See &ldquo;<I>Use of Proceeds</I>&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%"><B>Listing Symbols:</B></TD>
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: justify">NASDAQ:</TD>
    <TD STYLE="width: 58%">ONCY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">TSX:</TD>
    <TD>ONC</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>Risk Factors:</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">This investment involves a high degree of risk. You should carefully read and consider the information set forth under the heading &ldquo;<I>Risk Factors</I>&rdquo; beginning on page S-9 of this Prospectus Supplement and on page 6 of the Prospectus.</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</DIV>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_007"></A>RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective purchasers of Common Shares
should consider carefully the risk factors set out in this Prospectus Supplement, the Prospectus and the documents incorporated
by reference in the Prospectus. Discussions of certain risks affecting Oncolytics in connection with its business are set forth
under &ldquo;<I>Risk Factors</I>&rdquo; in the Prospectus and in our annual disclosure documents filed with the various securities
regulatory authorities which are incorporated by reference in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Volatility of market price of the Common
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of the Common Shares may
be volatile. The volatility may affect the ability of holders of Common Shares to sell the Common Shares at an advantageous price.
Market price fluctuations in the Common Shares may be due to the Corporation&rsquo;s operating results failing to meet the expectations
of securities analysts or investors in any quarter, downward revision in securities analysts&rsquo; estimates, governmental regulatory
action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements
by the Corporation or its competitors, along with a variety of additional factors, including, without limitation, those set forth
under &ldquo;<I>Special Notice Regarding Forward-Looking Statements</I>&rdquo; in this Prospectus Supplement. In addition, the
market price for securities in the stock markets, including the NASDAQ and the TSX, recently experienced significant price and
trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated
or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price
of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purchasers will suffer immediate and
substantial dilution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because the price of the Common Shares
under the Offering significantly exceeds the net tangible book value per share of the Common Shares, a purchaser of Common Shares
in the Offering will incur immediate and substantial dilution of his, her or its investment. If the Over-Allotment Option is exercised,
you will incur additional dilution. See &ldquo;<I>Dilution</I>&rdquo; in this Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Corporation will have broad discretion
over the use of the net proceeds from the Offering and the Corporation may not use these proceeds in a manner desired by the Corporation&rsquo;s
shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management will have broad discretion with
respect to the use of the net proceeds from the Offering and investors will be relying on the judgment of management regarding
the application of these proceeds. Management could spend most of the net proceeds from the Offering in ways that the Corporation&rsquo;s
shareholders may not desire or that do not yield a favorable return. You will not have the opportunity, as part of your investment
in the Common Shares, to influence the manner in which the net proceeds of the Offering are used. At the date of this Prospectus
Supplement, the Corporation intend to use the net proceeds from the Offering as described under the heading &ldquo;<I>Use of Proceeds</I>&rdquo;.
However, the Corporation&rsquo;s needs may change as the business and the industry the Corporation addresses evolve. As a result,
the proceeds to be received in the Offering may be used in a manner significantly different from the Corporation&rsquo;s current
expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Corporation does not currently intend
to pay any cash dividends on the Common Shares in the foreseeable future; therefore, the Corporation&rsquo;s shareholders may not
be able to receive a return on their Common Shares until they sell them</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has never paid or declared
any cash dividends on its Common Shares. The Corporation does not anticipate paying any cash dividends on its Common Shares in
the foreseeable future because, among other reasons, the Corporation currently intends to retain any future earnings to finance
its business. The future payment of dividends will be dependent on factors such as cash on hand and achieving profitability, the
financial requirements to fund growth, the Corporation&rsquo;s general financial condition and other factors the board of directors
of the Corporation may consider appropriate in the circumstances. Until the Corporation pays dividends, which it may never do,
its shareholders will not be able to receive a return on their Common Shares unless they sell them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You may be unable to enforce actions
against us, certain of our directors and officers, or the experts named in this Prospectus Supplement under U.S. federal securities
laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a company continued under the laws
of the Province of Alberta, Canada. Most of our directors and officers as well as the certain of the experts named in this Prospectus
Supplement and the accompanying Prospectus, reside principally in Canada. Because all or a substantial portion of our assets and
the assets of these persons are located outside of the United States, it may not be possible for you to effect service of process
within the United States upon us or those persons. Furthermore, it may not be possible for you to enforce against us or those persons
in the United States, judgments obtained in U.S. courts based upon the civil liability provisions of the U.S. federal securities
laws or other laws of the United States. There is doubt as to the enforceability, in original actions in Canadian courts, of liabilities
based upon U.S. federal securities laws and as to the enforceability in Canadian courts of judgments of U.S. courts obtained in
actions based upon the civil liability provisions of the U.S. federal securities laws. Therefore, it may not be possible to enforce
those actions against us, certain of our directors and officers or certain of the experts named in this Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Corporation is likely a &ldquo;passive
foreign investment company&rdquo; which may have adverse U.S. federal income tax consequences for U.S. shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">U.S. holders of Common Shares should be
aware that the Corporation believes it was classified as a passive foreign investment company (&ldquo;<B>PFIC</B>&rdquo;) during
the tax year ended December 31, 2017, and based on current business plans and financial expectations, the Corporation expects that
it will be a PFIC for the current tax year and may be a PFIC in future tax years. If the Corporation is a PFIC for any year during
a U.S. shareholder&rsquo;s holding period of the Common Shares, then such U.S. shareholder generally will be required to treat
any gain realized upon a disposition of Common Shares, or any &ldquo;excess distribution&rdquo; received on its Common Shares,
as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless the shareholder makes a timely
and effective &ldquo;qualified electing fund&rdquo; election (&ldquo;<B>QEF Election</B>&rdquo;) or a &ldquo;mark-to-market&rdquo;
election with respect to the Common Shares. A U.S. shareholder who makes a QEF Election generally must report on a current basis
its share of the Corporation&rsquo;s net capital gain and ordinary earnings for any year in which the Corporation is a PFIC, whether
or not the Corporation distributes any amounts to its shareholders. A U.S. shareholder who makes a mark-to-market election generally
must include as ordinary income each year the excess of the fair market value of the Common Shares over the taxpayer&rsquo;s adjusted
tax basis therein. This paragraph is qualified in its entirety by the discussion below under the heading &ldquo;Material United
States Federal Income Tax Considerations.&rdquo; Each U.S. shareholder should consult its own tax advisors regarding the PFIC rules
and the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_008"></A>THE CORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated
pursuant to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we amended our articles of incorporation
(the &ldquo;<B>Articles</B>&rdquo;) and changed our name to Oncolytics Biotech Inc. On July&nbsp;29, 1999, we amended our Articles
by removing the private company restrictions included therein and subdivided the 2,222,222 Common Shares issued and outstanding
into 6,750,000 Common Shares. On February&nbsp;9, 2007, we amended our Articles to permit shareholder meetings to be held at any
place in Alberta or at any other location as determined by our board of directors (the &ldquo;<B>Board</B>&rdquo;). On May 22,
2018, we amended our Articles of Incorporation to effect a consolidation (the &ldquo;<B>Consolidation</B>&rdquo;) of the Common
Shares on the basis of 9.5 pre-Consolidation Common Shares for each one post-Consolidation Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two material operating subsidiaries:
Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (US) Inc., a Delaware corporation. Oncolytics Biotech (Barbados) Inc.
is incorporated pursuant to the laws of Barbados and is a wholly-owned direct subsidiary of the Corporation. Oncolytics Biotech
(U.S.) Inc. is incorporated pursuant to the laws of Delaware and is a wholly-owned direct subsidiary or Oncolytics Biotech (Barbados)
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
4000, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_009"></A>RECENT DEVELOPMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purchase Agreement with Lincoln Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation and Lincoln Park have entered
into a Purchase Agreement dated September 28, 2018 which provides that, upon the terms and subject to the conditions and limitations
set forth therein, we have the right to sell to Lincoln Park up to US$26,000,000 worth of our Common Shares at our discretion as
described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are filing this prospectus supplement
with regard to the Offering of up to US$26,910,000 worth of our Common Shares, which consists of (i) 248,762 Common Shares that
Lincoln Park is purchasing as the initial purchase under the Purchase Agreement for gross proceeds of US$1,000,000 at a price of
US$4.0199 per Common Share, which was the closing price of the Common Shares on NASDAQ on September 27, 2018; (ii) the additional
Common Shares with an aggregate offering price of up to US$25,000,000 which we may sell from time to time, in our sole discretion,
to Lincoln Park over 30-month term of the Purchase Agreement subject to the conditions and limitations in the Purchase Agreement,
(iii) the 110,754 Initial Commitment Shares valued at US$US4.1802 per share for an aggregate value of US$455,000; and (iv) up to
an additional 110,754 Additional Commitment Shares that we may issue to Lincoln Park on a <I>pro rata</I> basis, upon each purchase
by Lincoln Park under the Purchase Agreement at a price of US$4.1082 per share for an aggregate value of US$455,000. The Corporation
agreed to issue the Commitment Shares and Additional Commitment Shares to the Investor as consideration for the entering into of
the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Purchase Agreement, on any business
day and as often as every other business day over the 30-month term of the Purchase Agreement, we have the right, in our sole discretion,
subject to the conditions and limitations in the Purchase Agreement, to direct Lincoln Park to purchase up to 50,000 Common Shares
(each a &ldquo;<B>Regular Purchase</B>&rdquo;). Such amount of the Regular Purchase may be increased to up to 75,000 Common Shares,
provided that the closing sale price of the Common Shares is not below US$5.00 on the applicable purchase date, and up to 100,000
Common Shares, provided that the closing sale price of the Common Shares is not below US$7.00 on the applicable purchase date;
however, Lincoln Park&rsquo;s obligation under each Regular Purchase shall not exceed $1,500,000, which may be increased upon the
mutual agreement of us and Lincoln Park. The purchase price for Common Shares to be purchased by Lincoln Park in a Regular Purchase
will be the lower of (i) the lowest sale price on the purchase date, as reported by NASDAQ, and (ii) the arithmetic average of
the three lowest closing sale prices for our Common Shares during the 12 consecutive business days prior to the purchase date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can also accelerate the amount of our
Common Shares to be purchased under certain circumstances in an amount up to the lesser of (i) 200% of the number of Common Shares
purchased pursuant to the applicable Regular Purchase and (ii) 30% of the trading volume on such accelerated purchase date, if
the closing sale price of our Common Shares equals or exceeds US$1.50 on such purchase date, as reported by NASDAQ (each an &ldquo;Accelerated
Purchase&rdquo;). The purchase price for the Common Shares in an Accelerated Purchase is the lower of (i) the closing sale price
for our Common Shares on the date of sale, and (ii) 95% of the volume weighted average price of our Common Shares on NASDAQ on
the date of sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no upper limit on the price per
share that Lincoln Park must pay for our common shares under the Purchase Agreement, but in no event will shares be sold to Lincoln
Park (i) on a day the closing sale price for the Common Shares is less than the floor price of US$1.00 per Common Share; or at
a price per share that is less than the volume weighted average trading price of the Common Shares on the TSX for the five immediately
preceding trading days, less the maximum applicable discount allowed by the TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no trading volume requirements
or restrictions under the Purchase Agreement, but there are limitations on the number of Common Shares we can direct Lincoln Park
to purchase, as described herein. We will control the timing and amount of any sales of our Common Shares to Lincoln Park. We may
at any time, in our sole discretion terminate the Purchase Agreement without fee, penalty or cost, upon one business days&rsquo;
notice. We may issue up to 110,754 Additional Commitment Shares as an additional commitment fee on a <I>pro rata</I> basis as Lincoln
Park purchases up to US$26,000,000 worth of our Common Shares in our discretion under the Purchase Agreement. By way of example
only, if we elect, at our sole discretion, to require Lincoln Park to purchase US$100,000 worth of our Common Shares, then we would
issue approximately 426 Additional Commitment Shares as a <I>pro rata</I> additional commitment fee, which is the product of US$100,000,
the amount we have elected to sell, divided by US$26,000,000, the total amount we can sell to Lincoln Park under the Purchase Agreement,
multiplied by 110,754, the maximum number of Additional Commitment Shares under the Purchase Agreement. The Additional Commitment
Shares will only be issued pursuant to this formula if, as and when we elect to sell our Common Shares to Lincoln Park. Lincoln
Park may not assign or transfer its rights or obligations under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement limits our sales
of Common Shares to Lincoln Park to 3,292,878 Common Shares, or 19.99% of our total outstanding Common Shares as of the date that
the Purchase Agreement was originally entered into (the &ldquo;<B>Exchange Cap</B>&rdquo;), unless and until we have obtained shareholder
approval of the transactions contemplated by the Purchase Agreement under applicable NASDAQ and TSX rules, provided that such limitation
shall not apply to the extent that the average price of all sales of Common Shares to Lincoln Park under the Purchase Agreement
exceed a &ldquo;base price&rdquo; of $4.2764, such that the sales to Lincoln Park are considered to be at least &ldquo;at market&rdquo;
under applicable NASDAQ rules. None of our Common Shares issued pursuant to the Purchase Agreement will be offered for sale or
sold by us or Lincoln Park on the TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement also prohibits us
from directing Lincoln Park to purchase any Common Shares if those Common Shares, when aggregated with all of our other Common
Shares then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial
ownership, at any single point in time, of more than 9.99% of our then total outstanding Common Shares (approximately 1,653,058
shares as of the date of this Prospectus Supplement), as calculated pursuant to Section 13(d) of the Exchange Act, and Rule 13d-3
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of Common Shares ultimately
offered for sale by the Corporation under this Prospectus Supplement is dependent upon the number of Common Shares purchased by
Lincoln Park under the Purchase Agreement. The following table sets forth the amount of proceeds we would receive from Lincoln
Park from the sale of Common Shares that are registered in the Offering at varying purchase prices (without accounting for certain
fees and expenses), assuming the sale by us of Common Shares in the aggregate amount of the US$26,000,000 in Common Shares at the
average prices set forth in the table, and including the issuance by the Corporation of 110,754 Commitment Shares and 110,754 Additional
Commitment Shares, in each case at a price of US4.1802 per Common Share for an aggregate value of US455,000:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Assumed Average Purchase<BR> Price for Additional Purchase<BR> Shares</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Number of Registered
    Shares<BR>
 to be Issued if Full Purchase</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Percentage of Outstanding<BR> Shares After Giving Effect to<BR> the Issuance to Lincoln Park</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Proceeds from the Sale of<BR> Shares to Lincoln Park Under<BR> the Purchase Agreement</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: justify">US$5.00</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,421,508</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">24.67</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">US$26,910,000</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">US$4.50</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,999,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26.60</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">US$26,910,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">US$4.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,721,508</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28.88</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">US$26,910,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">US$3.50</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,650,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31.61</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">US$26,910,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">US$3.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,888,175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34.94</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">US$26,910,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">US$2.50</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,621,508</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39.09</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">US$26,910,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Events of default under the Purchase Agreement
include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the effectiveness of the registration statement, of which this Prospectus Supplement and accompanying
Prospectus are a part, lapses for any reason (including, without limitation, the issuance of a stop order), or this Prospectus
Supplement and accompanying Prospectus or the Canadian Prospectus Supplement and accompanying Prospectus related to the Offering
hereby are unavailable for sale by us to Lincoln Park of our Common Shares offered hereby and thereby, respectively, and such lapse
or unavailability continues for a period of 10 consecutive business days or for more than an aggregate of 30 business days in any
365-day period;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspension by our principal market of our Common Shares from trading for a period of one business
day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the de-listing of our Common Shares from The NASDAQ Capital Market, provided our Common Shares
are not immediately thereafter trading on the New York Stock Exchange, The NASDAQ Global Market, The NASDAQ Global Select Market,
the NYSE MKT, the NYSE Arca, the OTC Bulletin Board or OTC Markets (or nationally recognized successor to any of the foregoing);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the transfer agent&rsquo;s failure for three business days to issue to Lincoln Park our Common
Shares after the applicable payment therefor;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any breach of the representations or warranties or covenants contained in the Purchase Agreement
or any related agreements which has had or which could have a material adverse effect on us, subject to a cure period of five business
days;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any participation or threatened participation in insolvency or bankruptcy proceedings by or against
us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if at any time we are not eligible to transfer our Common Shares electronically; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if at any time the Exchange Cap is reached (to the extent the Exchange Cap is applicable) and we
have not obtained shareholder approval of the transactions contemplated by the Purchase Agreement under applicable NASDAQ rules.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lincoln Park does not have the right to
terminate the Purchase Agreement upon any of the events of default set forth above. During an event of default, all of which are
outside the control of Lincoln Park, our Common Shares cannot be sold by us or purchased by Lincoln Park under the terms of the
Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering will terminate on the date
that all Common Shares offered by this Prospectus Supplement have been sold or, if earlier, the expiration or termination of the
Purchase Agreement. We have the right to terminate the Purchase Agreement at any time, at no cost to us. In the event of bankruptcy
proceedings by or against us, the Purchase Agreement will automatically terminate without action of any party.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_010"></A>BUSINESS OF THE CORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in April of 1998, Oncolytics
Biotech Inc. has been a development stage company and we have focused our research and development efforts on the development of
pelareorep, a systemically administered immuno-oncology (&ldquo;<B>I-O</B>&rdquo;) viral agent with the potential to treat a variety
of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research
and development efforts. We do not expect to generate significant revenues until, if and when, pelareorep becomes commercially
viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our potential product for human use, pelareorep,
an unmodified reovirus, is a first in class systemically administered I-O viral agent for the treatment of solid tumors and hematological
malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Scientific Background </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pelareorep&rsquo;s anti-tumor activity
is based on three modes of action which are complementary but not interdependent (see Figure 1, below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Selective viral replication in permissive cancer cells which leads to tumor cell lysis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Activation of innate immunity in response to the infection which results in a cascade of chemokines/cytokines
causing natural killer (&ldquo;<B>NK</B>&rdquo;) cells to be activated and attack cancer cells.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A specific adaptive immune response triggered by tumor- and viral-associated antigens displayed
by antigen-presenting cells (including infected tumor cells and/or dendritic cells, &ldquo;<B>APCs</B>&rdquo;) to T cells.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary of Research and Development
highlights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical and Translational Research
data to date indicate the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep has anticancer effects in models of metastatic cancers that can prolong survival in
these models when using immuno-competent rodents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The survival benefit in animal models can be enhanced when pelareorep is given in combination with
chemotherapy, immunotherapy (e.g., checkpoint inhibitors, IMiDs, rituximab, etc.) or radiotherapy.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A toxic dose of reovirus T3D has not been reached/established in animal models and infection presents
with minimal side-effects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical data to date indicate the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">More than 1,400 patients have been enrolled in clinical studies conducted in the United States,
Canada and the European Union. Of these, more than 1,000 patients received pelareorep, with over 930 via intravenous (&ldquo;<B>IV</B>&rdquo;)
administration and over 90 by intratumoral injections (&ldquo;<B>ITu</B>&rdquo;). The remaining patients were randomized to control
arms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either
as a mono-therapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and radiotherapy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">No Maximum Tolerated Dose (&ldquo;<B>MTD</B>&rdquo;) for intravenous pelareorep as mono-therapy
was defined in the two Phase 1 studies (REO 004 and 005). Dose-limiting toxicities (&ldquo;<B>DLTs</B>&rdquo;) were seen in some
of the combination trials with pelareorep and chemotherapy, which generally enrolled heavily pre-treated patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">When combined with chemotherapeutic agents, pelareorep does not appear to enhance either the frequency
or severity of the adverse effects of the chemotherapeutic agents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">There is emerging evidence that pelareorep may impact overall survival (&ldquo;<B>OS</B>&rdquo;)
in metastatic breast cancer (MBC) and metastatic adenocarcinoma of the pancreas (&ldquo;<B>MAP</B>&rdquo;):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In a randomized, controlled Phase 2 study of paclitaxel with pelareorep versus paclitaxel alone
in MBC (CCTG IND. 213) median survival time was greater for subjects treated with paclitaxel and pelareorep (median 17.4 months)
than subjects treated with paclitaxel alone (10.4 months, hazard ratio (&ldquo;<B>HR</B>&rdquo;) 0.65).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In a single arm study with gemcitabine plus pelareorep in first line MAP (REO 017) the median overall
survival (mOS) was 10 months with a 1-year and 2-year survival of 46% and 24%, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">In a two-arm Phase 2 randomized study (NCI 8601), patients with MAP were randomized to receive
either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). The median OS was similar
for both arms, but the probability of survival at Year 2 was 20% in the test arm compared to 9% in the control arm.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mechanism of Action </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Figure 1. Proposed mechanism of action for pelareorep.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv503751_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Direct cell lysis - Reovirus Replication in Permissive
Cancer Cells</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selective viral replication and lysis in
cancer cells and not normal cells is mediated by the host cellular protein PKR (dsRNA-activated protein kinase). In non-cancer
cells that are infected with reovirus, PKR activates in the presence of the virus which in turn inhibits viral gene translation.
However, in permissive cancer cells, PKR activation is inhibited, allowing for viral gene translation and eventual cell lysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It was originally established that selective
lysis with reovirus was mediated by tumor cells with an activated RAS-pathway, since active RAS inhibits PKR activation. However,
more recent investigations have revealed that reovirus replication is not just restricted to cells with an active RAS pathway,
oncogenic mutations and amplifications in upstream (&ldquo;<B>EGFR</B>&rdquo;) and downstream (&ldquo;<B>BRAF</B>&rdquo;) mediators
of the RAS-pathway also allow for viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream
effector proteins, many of which have been shown to facilitate viral replication, such as activation of Raf/MEK/ ERK, RalGEF/p38,
and JNK signalling pathways. Cells bearing dysfunctional or deleted tumor suppressor genes (p53, ATM and Rb) and or chemo- or radiation-induced
cell stress also show increased sensitivity to reovirus replication and lysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Induction of Innate Immunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical and clinical studies provide
compelling lines of evidence that pelareorep functions as an immunogenic agent. Indeed, preclinical studies by Steele and colleagues
demonstrated that melanoma cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory
cytokines. This inflammatory milieu promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T-cells, altering
the tumour microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also
demonstrated that the beneficial immunogenic functions of pelareorep can occur independent of viral replication. Pelareorep performs
this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic
cells activated by reovirus in turn stimulate the innate antitumor activity of NK (natural killer) cells through the release of
proinflammatory cytokines, demonstrating that dendritic cells&rsquo; recognition of reovirus may trigger a beneficial innate immune
response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A clinical trial with pelareorep (REO 013)
provided an opportunity to study human NK cell activation, in humans, in a controlled manner. Ten colorectal cancer patients with
liver metastases received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation
peaked 24 to 48 hours post-infection, coincident with a peak of pro-inflammatory cytokines. NK cells within reovirus-treated blood
mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover, NK cells were able to hand-off virus
to tumors for direct oncolytic killing. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards
tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity in vivo and suggest
that this may contribute to the therapeutic effect of pelareorep.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 14; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Induction of Adaptive Immunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adaptive anti-tumor immunity allows for
elimination of existing cancer cells and performs constant surveillance, preventing relapse, and increasing patient overall survival.
An adaptive immune response requires two signals: a signal from an APC, as well as a co-stimulation signal in the form of cytokines.
In the absence of both signals, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both
signals. Following its therapeutic administration, pelareorep enhances the expression of &lsquo;foreign&rsquo; antigens/markers
on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (&ldquo;<B>TAAs</B>&rdquo;) and viral-associated antigens
(&ldquo;<B>VAAs</B>&rdquo;) for processing and presentation by APCs, such as dendritic cells. Through the combined actions of these
immunological events, pelareorep facilitates the display of novel &lsquo;foreign&rsquo; antigens on the surface of infected tumor
cells and APCs. Simultaneously, pelareorep induces an inflammatory response promoting the expression of co-stimulatory molecules
and inflammatory cytokines. Together, pelareorep mediated immunological events over-rule tumor antigen presentation impairments
and initiate adaptive anti-tumor immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By promoting the expression of novel antigens
and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized
by NK and T-cell infiltration, increased expression of chemokines/ cytokines, and increased expression of checkpoint ligands. This
phenotype correlates with an increase in overall survival and has a positive prognostic value for early stage cancers. In patients
with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies,
including immune checkpoint blockade inhibitors, cancer vaccines, and adoptive T-cell therapies. By promoting an inflamed tumor
phenotype, pelareorep primes an anti-cancer immune response (see Figure 2, below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Figure 2. Pelareorep primes an anti-cancer immune response</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv503751_img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clinical Development Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are directing a three-part clinical
development program with the objective of developing pelareorep as a human cancer therapeutic. Our clinical development program
focuses on the three components of pelareorep&rsquo;s mechanism of action and includes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 15; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Chemo combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary focus has been on the investigation
of chemotherapy combination clinical trials investigating the use of different chemotherapy agents in various cancer indications.
In 2017, we reported additional clinical data from our randomized clinical program which includes the clinical trial collaborations
with the Canadian Cancer Trials Group (&ldquo;<B>CCTG</B>&rdquo;, formerly known as the National Cancer Institute of Canada). Specifically,
subgroup analysis in the IND.213 trial in MBC revealed a significant improvement in overall survival of patients that are hormone
receptor positive (&ldquo;<B>HR+</B>&rdquo;) / human epidermal growth factor receptor 2 negative (&ldquo;<B>HER2-</B>&rdquo;).
In HR+/HER2- patients, pelareorep therapy in combination with paclitaxel doubled the overall survival from 10.8 month with paclitaxel
therapy alone to 21.8 months with pelareorep plus paclitaxel. This increase in overall survival is consistent with previous survival
data reported from our NCI pancreatic trial which suggests a long term survival benefit when comparing test and control arms at
24 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Combination with IMiDs/targeted therapy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our second program focuses on the potential
of pelareorep to stimulate a patient&rsquo;s innate immunity and the potential for an infection to cause a cascade of chemokines/cytokines
activating NK cells to attack cancer cells. In 2017, patient enrollment commenced on a clinical collaboration with Myeloma UK and
Celgene that combines pelareorep with immune modulator therapies (&ldquo;<B>IMiDs</B>&rdquo;) which enhance NK cell activation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Immunotherapy combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our third program focuses on the potential
for pelareorep to cause a specific adaptive immune response triggered by tumor- and viral-associated antigens displayed by APCs
to T cells. In 2017 we announced our first data set combining a checkpoint inhibitor with pelareorep and pembrolizumab (Keytruda&reg;)
in pancreatic cancer, which demonstrated safety and tolerability and in five efficacy evaluable patients, one had a partial response
(six-month duration) and two had stable disease (lasting 126 and 221 days). Additional basket study concepts are now being planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business strategy is to develop and
market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe
is best for our development. We intend to achieve our business strategy by focusing on these key areas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Develop pelareorep through our clinical development plan assessing the safety and efficacy in human
subjects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Establish collaborations with experts to assist us with scientific and clinical developments of
this new potential pharmaceutical product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Implement strategic alliances with selected pharmaceutical and biotechnology companies and selected
laboratories, at a time and in a manner where such alliances may complement and expand our research and development efforts on
the product and provide sales and marketing capabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Utilize our broadening patent base and collaborator network as a mechanism to meet our strategic
objectives; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Develop relationships with companies that could be instrumental in assisting us to access other
innovative therapeutics.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business strategy is based on attaining
a number of commercial objectives, which, in turn, are supported by a number of product development goals. Our new product development
presently being conducted is primarily of a research and development nature. In this Prospectus Supplement, statements of our &ldquo;belief&rdquo;
are based primarily upon our results derived to date from our research and development program with animals, early stage human
trials and our most recent data in HR+/HER2- mBC patients, and upon which we believe that we have a reasonable scientific basis
to expect the particular results to occur. It is not possible to predict, based upon studies in animals, or early stage human trials,
whether a new therapeutic will ultimately prove to be safe and effective in humans. There are no assurances that the particular
result expected by us will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, we do not intend
to become a fully integrated pharmaceutical company with substantial in-house research and development, marketing and distribution
or manufacturing capabilities. We are pursuing a strategy of establishing relationships with larger companies as strategic partners.
We intend to partner or joint venture with larger pharmaceutical companies that have existing and relevant marketing capability
for our products. It is anticipated that future clinical development into large international or pivotal trials would generally
occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance. In exchange
for certain product rights and commitments to market our products, the strategic partners would be expected to share in gross proceeds
from the sale of our product or products and potentially share in various market or manufacturing opportunities. The proceeds generated
from partnering or joint venturing projects are expected to be distributed on the basis of relative risk taken and resources contributed
by each party to the partnership or joint venture.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_011"></A>USE OF PROCEEDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because it is uncertain how many Common
Shares will be sold or the prices at which the shares will be sold, the net proceeds to the Corporation from the sale of shares
to Lincoln Park pursuant to this Prospectus Supplement cannot be determined at this time. Assuming the Corporation sells shares
and issues the related Additional Commitment Shares for no cash consideration such that the full US$26,000,000 in Common Shares
(excluding the Commitment Shares and Additional Commitment Shares) qualified by this Prospectus Supplement are issued, the estimated
net proceeds of the Offering will be approximately US$25,800,000 million after estimated expenses of US$200,000 payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming estimated net proceeds of approximately
US$25,800,000 million, we intend to use the net proceeds from the Offering, if any, for the advancement of the Corporation&rsquo;s
clinical development program, related support costs and general corporate and administrative expenses. General corporate and administrative
expenses may include funding ongoing operations and/or capital requirements, discretionary capital programs and potential future
acquisitions. Although, the Corporation intends to expend the net proceeds from the Offering as set forth above, there may be circumstances
where for sound business reasons, a reallocation of funds may be deemed prudent or necessary, and may vary materially from that
set forth above. Pending the uses described above, we plan to invest the net proceeds from the Offering in short- and intermediate-term,
interest bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the
U.S. government..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts actually expended for the purposes
described above may vary significantly depending upon a number of factors, including those listed under the heading &ldquo;<I>Risk
Factors</I>&rdquo; in this Prospectus Supplement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_012"></A>CONSOLIDATED CAPITALIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has not been any material change
in the share and loan capital of the Corporation, on a consolidated basis, since the Corporation&rsquo;s most recently filed financial
statements for the six months ended June 30, 2018.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_013"></A>TRADING PRICE AND
VOLUME</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Shares are listed and posted
for trading on the TSX under the trading symbol &ldquo;ONC&rdquo; and on the NASDAQ under the trading symbol &ldquo;ONCY&rdquo;.
Prior to the commencement of trading of the Common Shares on NASDAQ on June 1, 2018, the Common Shares were quoted for trading
on the OTCQX under the trading symbol &ldquo;ONCYD&rdquo;. On September 27, 2018, the closing price of our Common Shares on the
TSX was C$5.21 and the closing bid price of our Common Shares on the NASDAQ was US$4.0199.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the market
price ranges and the aggregate volume of trading of the Common Shares on the TSX, NASDAQ and OTCQX for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="9" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>TSX<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="9" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>OTCQX / NASDAQ<SUP>(1)(2)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Close</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Volume</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Close</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Volume</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(C$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(C$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(C$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Shares)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(US$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(US$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(US$)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Shares)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: left"><U>2017</U></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 24%; text-align: left">September</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">6.84</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">4.75</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">5.985</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">608,338</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">5.605</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">3.80</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">4.94</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">245,684</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">October</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.27</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.035</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.415</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">248,538</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3.895</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.18</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,526</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">November</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.225</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.65</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">837,293</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.365</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3.99</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">533,410</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">December</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.41</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.27</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.745</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">409,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.795</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.845</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.415</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">January</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10.64</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.555</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.03</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,219,326</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.55</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.225</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.70</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">837,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">February</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.60</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.51</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.60</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">568,884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.89</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.275</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.795</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">611,621</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">March</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.08</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.27</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341,092</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.365</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.75</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.845</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">553,189</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">April</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.315</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.795</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.175</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.70</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.465</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.56</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">343,589</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">May</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10.650</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.795</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.20</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,088,818</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.075</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.465</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,182,710</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">June</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.60</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.05</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">668,081</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.31</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.44</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,089,953</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">July</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.12</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.50</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219,686</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.0371</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.70</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.96</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">521,344</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">August</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.76</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.23</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.46</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">447,865</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.40</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.89</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.18</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,362,577</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">September 1 to 27</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.52</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.21</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,013</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.1199</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3.77</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.0199</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,326,974</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">On May 22, 2018, the Corporation completed the Consolidation of its Common Shares on the basis
of 9.5 pre-Consolidation Common Shares for each one post-Consolidation Common Share. Information is presented as though the Consolidation
occurred on August 31, 2017.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The Common Shares commenced trading on NASDAQ on June 1, 2018. Information provided for dates prior
to June 1, 2018 reflects inter-dealer prices on the OTCQX without retail mark-up, mark-down or commission and may not represent
actual transactions and information from and after June 1, 2018 reflects the market price ranges of the Common Shares on the NASDAQ.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_014"></A>PRIOR SALES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed under this heading,
no other Common Shares or securities exchangeable or convertible into Common Shares have been issued during the twelve month period
preceding the date of this Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus Supplement, the Corporation issued an aggregate of 1,861,968 Common Shares (after giving effect to
adjustments arising as a consequence of the Consolidation), the particulars of which are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date of Issue</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Number of Common Shares Issued<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Price per Common Share (US$)<SUP>(1)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%">September 18, 2017</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">2,368</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">4.37</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 20, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12,052</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.23</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>September 20, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">79,842</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4.845</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 21, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">19,631</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.13</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>September 22, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4.94</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 2, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3,052</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4.37</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>November 21, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">110,947</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.795</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>December 4, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5,368</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.225</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>January 12, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">42,894</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8.075</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>January 15, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11,789</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8.075</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>May 2, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.04</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>May 4, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">52</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.04</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>May 7, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2,210</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.04</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>May 7, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,052</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.09</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>May 8, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2,105</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.09</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>May 9, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,052</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.09</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>June 5, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,532,278</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.83</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>June 18, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">157</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6.83</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>July 16, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10,526</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1.88</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 12, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6,473</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.82</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>September 17, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.04</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 18, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5,700</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.39</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>September 27, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4,420</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2.39</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">On May 22, 2018, the Corporation completed the Consolidation of its Common Shares on the basis
of 9.5 pre-Consolidation Common Shares for each one post-Consolidation Common Share. Information is provided on a post-Consolidation
basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus Supplement, the Corporation granted stock options pursuant to its amended and restated stock option
plan exercisable for an aggregate of 337,559 Common Shares (after giving effect to adjustments arising as a consequence of the
Consolidation). The particulars of such grants are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date of Grant</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Number of Options Granted<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exercise Price (C$)<SUP>(1)</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%">November 1, 2017</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">1,578</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">5.42</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 7, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5,263</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.42</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>November 16, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4,736</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.42</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>March 8, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">307,042</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.41</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>April 2, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3,157</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6.27</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>April 23, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2,105</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6.46</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>May 1, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,578</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.80</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>July 9, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.81</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>August 7, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2,100</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.78</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 20, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1,500</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5.67</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">On May 22, 2018, the Corporation completed the Consolidation of its Common Shares on the basis
of 9.5 pre-Consolidation Common Shares for each one post-Consolidation Common Share. Information is provided on a post-Consolidation
basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Share Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the twelve month period preceding
the date of this Prospectus Supplement, the Corporation granted restricted share awards pursuant to its amended and restated incentive
share award plan which, upon vesting, will entitle the holders thereof to receive up to an aggregate of 42,434 Shares (after giving
effect to adjustments arising as a consequence of the Consolidation). The particulars of such grants are set forth in the following
table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 66%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Date of Grant</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Share Awards Granted<SUP>(1)</SUP></B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">September 30, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">3,963</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 16, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2,105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>December 1, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">23,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">3,647</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>March 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">6,786</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>April 2, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2,105</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">On May 22, 2018, the Corporation completed the Consolidation of its Common Shares on the basis
of 9.5 pre-Consolidation Common Shares for each one post-Consolidation Common Share. Information is provided on a post-Consolidation
basis.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_015"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to this Prospectus Supplement,
we are offering up to US$26,910,000 of our Common Shares that may be issued by us directly to Lincoln Park under the Purchase Agreement,
including (i) 248,762 of our Common Shares that Lincoln Park is purchasing for gross proceeds of US$1,000,000 as an initial purchase,
at a purchase price of US$4.0199 per Common Share; (ii) up to US$25,000,000 of our Common Shares that may be sold from time to
time after the initial purchase, at our sole discretion, to Lincoln Park over the 30 month period which commenced on September
28, 2018 in accordance with the Purchase Agreement; (iii) 110,754 Initial Commitment Shares to be issued to Lincoln Park as consideration
for the entering into of the Purchase Agreement, valued at US$4.1082 per Common Share for a total aggregate value of app US$455,000
issued under this Prospectus Supplement; and (iv) up to 110,754 Additional Commitment Shares, valued at US$4.1082 per Common Share,
that we may issue to Lincoln Park on a <I>pro rata</I> basis, upon each purchase by Lincoln Park under the Purchase Agreement (including
the initial purchase of US$1,000,000 of Common Shares). This Prospectus Supplement also qualifies for distribution the resale of
these Common Shares by Lincoln Park to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation and Lincoln Park have entered
into a Purchase Agreement dated September 28, 2018. The Purchase Agreement provides that, upon the terms and subject to the conditions
set forth therein, Lincoln Park is irrevocably committed to purchase an aggregate of up to US$26,000,000 worth of our Common Shares
over the 30-month period which commenced on September 28, 2018 under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement provides that, from
time-to-time over the term of the Purchase Agreement, on any business day, and as often as other business day, and at our sole
discretion, we may require Lincoln Park to purchase up to 50,000 of our Common Shares in a Regular Purchase. Such amount of the
Regular Purchase may be increased to up to 75,000 Common Shares, provided that the closing sale price of the Common Shares is not
below US$5.00 on the applicable purchase date, and up to 100,000 Common Shares, provided that the closing sale price of the Common
Shares is not below US$7.00 on the applicable purchase date; however, Lincoln Park&rsquo;s obligation under each Regular Purchase
shall not exceed $1,500,000, which may be increased upon the mutual agreement of us and Lincoln Park. We can also accelerate the
amount of our Common Shares to be purchased under certain circumstances in an Accelerated Purchase in an amount up to the lesser
of (i) 200% of the number of Common Shares purchased pursuant to the applicable Regular Purchase and (ii) 30% of the trading volume
on such accelerated purchase date, provided that the closing sale price of our Common Shares equals or exceeds US$1.50 on such
purchase date, as reported by NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement limits our sales
of Common Shares to Lincoln Park to the Exchange Cap, which is 3,292,878 Common Shares, or 19.99% of our total outstanding Common
Shares as of the date that the Purchase Agreement was originally entered into, unless and until we have obtained shareholder approval
of the transactions contemplated by the Purchase Agreement under applicable NASDAQ rules, provided that such limitations shall
not apply to the extent that the average price of all sales of Common Shares to Lincoln Park under the Purchase Agreement exceed
a &ldquo;base price&rdquo; of US$4.2764, such that the sales to Lincoln Park are considered to be at least &ldquo;at market&rdquo;
under applicable NASDAQ rules. None of our Common Shares issued pursuant to the Purchase Agreement will be offered for sale or
sold by us or Lincoln Park on the TSX or to purchasers resident in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement also prohibits us
from directing Lincoln Park to purchase any Common Shares if those Common Shares, when aggregated with all of our other Common
Shares then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial
ownership, at any single point in time, of more than 9.99% of our then total outstanding Common Shares (as calculated pursuant
to Section 13(d) of the Exchange Act and Rule 13d-3 thereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may suspend the sale of Common Shares
to Lincoln Park pursuant to this Prospectus Supplement for certain periods of time for certain reasons, including if this Prospectus
Supplement is required to be supplemented or amended to include additional material information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering will terminate on the date
that all Common Shares offered by this Prospectus Supplement have been sold or, if earlier, the expiration or termination of the
Purchase Agreement. We have the right to terminate the Purchase Agreement at any time, at no cost to us. In the event of bankruptcy
proceedings by or against us, the Purchase Agreement will automatically terminate without action of any party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering has been approved by NASDAQ
and the TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immediately prior to the date of the Purchase
Agreement, Lincoln Park beneficially owned none of our Common Shares. Josh Scheinfeld and Jonathan Cope, the Managing Members of
Lincoln Park Capital, LLC, the manager of Lincoln Park, are deemed to be beneficial owners of all of the Common Shares owned by
Lincoln Park. Messrs. Cope and Scheinfeld have shared voting and investment power over the Common Shares being offered under this
Prospectus Supplement filed with the SEC in connection with the transactions contemplated under the Purchase Agreement. Lincoln
Park Capital, LLC is not a licensed broker dealer or an affiliate of a licensed broker dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lincoln Park is an &ldquo;underwriter&rdquo;
within the meaning of Section 2(a)(11) of the Securities Act. Lincoln Park has informed us that it will use a broker-dealer unaffiliated
with Lincoln Park to effectuate all sales, if any, of the Common Shares that it may purchase from us pursuant to the Purchase Agreement.
Such sales will be made on NASDAQ at prices and at terms then prevailing or at prices related to the then current market price.
Each such unaffiliated broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lincoln Park has informed us that each
such broker-dealer will receive commissions from Lincoln Park that will not exceed customary brokerage commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We know of no existing arrangements between
Lincoln Park and any other shareholder, broker, dealer, underwriter, or agent relating to the sale or distribution of our Common
Shares offered by this Prospectus Supplement. At the time a particular offer of our Common Shares is made, a Prospectus Supplement,
if required, will be distributed that will set forth the names of any agents, underwriters, or dealers and any compensation from
the selling shareholder, and any other required information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will pay all of the expenses incident
to the registration, Offering, and sale of our Common Shares to Lincoln Park.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify Lincoln Park
against certain liabilities in connection with the Offering of our Common Shares offered hereby, including liabilities arising
under the Securities Act to the extent permissible by law or, if such indemnity is unavailable, to contribute amounts required
to be paid in respect of such liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that
in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lincoln Park represented to us that at
no time prior to the date of the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates engaged in or
effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO
of the Exchange Act) of our Common Shares or any hedging transaction. Lincoln Park agreed that during the term of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Purchase Agreement, it and its agents,
representatives and affiliates will not enter into or effect, directly or indirectly, any of the foregoing transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have advised Lincoln Park that it is
required to comply with Regulation M promulgated under the Exchange Act, to the extent applicable to the Offering. With certain
exceptions, Regulation M precludes the selling shareholder, any affiliated purchasers, and any broker-dealer or other person who
participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any
security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids
or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the
foregoing may affect the marketability of the shares offered by this Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent for our Common Shares
is Computershare Trust Company of Canada at its principal office in Calgary, Alberta.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our outstanding Common Shares are listed
and posted for trading on the TSX under the symbol &ldquo;ONC&rdquo; and on NASDAQ under the symbol &ldquo;ONCY&rdquo;. The TSX
has approved the listing of up to 3,529,278 of our Common Shares in connection with the Purchase Agreement (including the Commitment
Shares and Additional Commitment Shares). The issuance of any Common Shares under the Purchase Agreement in excess of 3,529,278
Common Shares (including the Commitment Shares and Additional Commitment Shares) will be subject to the approval of the TSX.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_016"></A>CERTAIN CANADIAN
FEDERAL INCOME TAX CONSIDERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is, as of the date of this
Prospectus Supplement, a summary of the principal Canadian federal income tax considerations under the <I>Income Tax Act </I>(Canada)
(&ldquo;<B>Tax Act</B>&rdquo;) and the regulations thereunder generally applicable to an investor who acquires as beneficial owner
Common Shares pursuant to the Offering and who, for the purposes of the Tax Act and at all relevant times deals at arm&rsquo;s
length with the Company and Lincoln Park, is not affiliated with the Company or Lincoln Park, is not exempt from tax under
Part I of the Tax Act, and who acquires and holds the Common Shares, as capital property (a &ldquo;<B>Holder</B>&rdquo;). Generally,
the Common Shares will be considered to be capital property to a Holder thereof provided that the Holder does not use the Common
Shares in the course of carrying on a business of trading or dealing in securities and such Holder has not acquired them or been
deemed to have acquired them in one or more transactions considered to be an adventure or concern in the nature of trade.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is generally applicable to
a Holder who, at all relevant times, for purposes of the Tax Act: (i) is not, and is not deemed to be, resident in Canada for the
purposes of the Tax Act or any applicable income tax treaty or convention; and (ii) does not and will not use or hold, and is not
and will not be deemed to hold, the Common Shares in connection with carrying on a business in Canada (&ldquo;<B>Non-Resident Holders</B>&rdquo;).
This summary is not applicable to a Non-Resident Holder that is (i) an insurer carrying on an insurance business in Canada and
elsewhere; or (ii) an &ldquo;authorized foreign bank&rdquo; (as defined in the Tax Act). Such Holders should consult their own
tax advisors with respect to an investment in Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is based upon the current
provisions of the Tax Act and the Regulations in force as of the date hereof and counsel&rsquo;s understanding of the administrative
policies and assessing practices of the Canada Revenue Agency (the &ldquo;<B>CRA</B>&rdquo;) published in writing by the CRA prior
to the date hereof. This summary takes into account all specific proposals to amend the Tax Act and the Regulations publicly announced
by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the &ldquo;<B>Tax Proposals</B>&rdquo;) and assumes
that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be
enacted in their current form or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the Tax Proposals, this summary
does not otherwise take into account or anticipate any changes in law, whether by legislative, governmental, administrative or
judicial decision or action, nor does it take into account or consider any provincial, territorial or foreign income tax considerations,
which considerations may differ significantly from the Canadian federal income tax considerations discussed in this summary. This
summary also does not take into account any change in the administrative policies or assessing practices of the CRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This summary is of a general nature
only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be
construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors with respect to their
particular circumstances.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Currency</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the Tax Act, all amounts
relating to the acquisition, holding or disposition of the Common Shares (including dividends, adjusted cost base and proceeds
of disposition) must be expressed in Canadian dollars based on the daily noon rate as quoted by the Bank of Canada for the applicable
day or such other rate of exchange that is acceptable to the CRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends paid or credited or deemed to
be paid or credited to a Non-Resident Holder by the Company are subject to Canadian withholding tax at the rate of 25% on the gross
amount of the dividend unless such rate is reduced by the terms of an applicable tax treaty. For example, under the Canada-United
States Tax Convention (1980), as amended (the &ldquo;<B>Treaty</B>&rdquo;), the rate of withholding tax on dividends paid or credited
to a beneficially entitled Non-Resident Holder who is resident in the U.S. for purposes of the Treaty and who is fully entitled
to the benefits of the Treaty (a &ldquo;<B>U.S. Holder</B>&rdquo;) is generally limited to 15% of the gross amount of the dividend
(or 5% in the case of a U.S. Holder that is a corporation beneficially owning at least 10% of the Company&rsquo;s voting shares).
Non-Resident Holders are urged to consult their own tax advisors to determine their entitlement to relief under an applicable income
tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dispositions of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon a disposition (or a deemed disposition)
of a Common Share (other than to the Company unless purchased by the Company in the open market in the manner in which shares are
normally purchased by any member of the public in the open market), a Non-Resident Holder generally will realize a capital gain
(or a capital loss) equal to the amount by which the proceeds of disposition of such security, as applicable, net of any reasonable
costs of disposition, are greater (or are less) than the adjusted cost base of such security to the Non-Resident Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Non-Resident Holder generally will not
be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a Common
Share, unless the Common Share constitutes &ldquo;taxable Canadian property&rdquo; to the Non-Resident Holder thereof for purposes
of the Tax Act, and the Non-Resident Holder is not entitled to relief under the terms of an applicable tax treaty. In addition,
capital losses arising on the disposition or deemed disposition of a Common Share will not be recognized under the Tax Act, unless
the Common Share constitutes &ldquo;taxable Canadian property&rdquo; to the Non-Resident Holder thereof for purposes of the Tax
Act, and the Non-Resident Holder is not entitled to relief under the terms of an applicable tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided the Common Shares are listed on
a &ldquo;designated stock exchange&rdquo;, as defined in the Tax Act (which currently includes the NASDAQ and TSX), at the time
of disposition, the Common Shares generally will not constitute taxable Canadian property of a Non-Resident Holder at that time,
unless at any time during the 60 month period immediately preceding the disposition the following two conditions are met concurrently:
(i) one or any combination of (a) the Non-Resident Holder, (b) persons with whom the Non-Resident Holder did not deal at arm&rsquo;s
length, or (c) partnerships in which the Non-Resident Holder or a person with whom the Non-Resident Holder did not deal at arm&rsquo;s
length held a membership interest directly or indirectly through one or more partnerships owned 25% or more of the issued shares
of any class or series of shares of the Company; and (ii) more than 50% of the fair market value of the shares of the Company was
derived directly or indirectly from one or any combination of (a) real or immovable property situated in Canada, (b) &ldquo;Canadian
resource properties&rdquo; (as defined in the Tax Act), (c) &ldquo;timber resource properties&rdquo; (as defined in the Tax Act)
or (d) an option, an interest or right in any of the foregoing property, whether or not such property exists. Notwithstanding the
foregoing, a Common Share may otherwise be deemed to be taxable Canadian property to a Non-Resident Holder for purposes of the
Tax Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-Resident Holders whose Common Shares
are taxable Canadian property should consult their own tax advisors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_017"></A>MATERIAL UNITED STATES
FEDERAL INCOME TAX CONSIDERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a general summary of certain
material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the
acquisition, ownership, and disposition of Common Shares acquired pursuant to this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is for general information
purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations
that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares. In addition,
this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the
U.S. federal income tax consequences to such U.S. Holder, including, without limitation, specific tax consequences to a U.S. Holder
under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or
U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum,
U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership,
and disposition of Common Shares. In addition, except as specifically set forth below, this summary does not discuss applicable
tax reporting requirements. Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal
alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition,
ownership and disposition of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No legal opinion from U.S. legal counsel
or ruling from the Internal Revenue Service (the &ldquo;<B>IRS</B>&rdquo;) has been requested, or will be obtained, regarding the
U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares. This summary is not binding
on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in
this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS
and the U.S. courts could disagree with one or more of the conclusions described in this summary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Scope of this Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Authorities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is based on the Internal Revenue
Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;), Treasury Regulations (whether final, temporary, or proposed), published
rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America
with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the &ldquo;<B>Canada-U.S. Tax Convention</B>&rdquo;),
and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document. Any
of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change
could be applied retroactively. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed
legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>U.S. Holders</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this summary, the term
 &quot;<B>U.S. Holder</B>&quot; means a beneficial owner of Common Shares acquired pursuant to this Offering that is for U.S. federal
income tax purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an individual who is a citizen or resident of the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized
under the laws of the United States, any state thereof or the District of Columbia;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify; text-indent: -0.35in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control
of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations
to be treated as a U.S. person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>U.S. Holders Subject to Special U.S.
Federal Income Tax Rules Not Addressed</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary does not address the U.S.
federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including,
but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts,
or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts,
or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply
a mark-to-market accounting method; (d) have a &ldquo;functional currency&rdquo; other than the U.S. dollar; (e) own Common Shares
as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than
one position; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation
for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property
held for investment purposes); or (h) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the
total combined voting power or value of the outstanding shares of the Company. This summary also does not address the U.S. federal
income tax considerations applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b)
persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the <I>Income Tax Act</I>
(Canada) (the &ldquo;<B>Tax Act</B>&rdquo;); (c) persons that use or hold, will use or hold, or that are or will be deemed to use
or hold Common Shares in connection with carrying on a business in Canada; (d) persons whose Common Shares constitute &ldquo;taxable
Canadian property&rdquo; under the Tax Act; or (e) persons that have a permanent establishment in Canada for the purposes of the
Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions under the Code, including, but not limited to,
U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative
minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership
and disposition of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an entity or arrangement that is classified
as a partnership (or other &ldquo;pass-through&rdquo; entity) for U.S. federal income tax purposes holds Common Shares, the U.S.
federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity
or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners
or participants). This summary does not address the tax consequences to any such partner (or owner or participants). Partners (or
other owners or participants) of entities or arrangements that are classified as partnerships or as &ldquo;pass-through&rdquo;
entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences
arising from and relating to the acquisition, ownership, and disposition of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Passive Foreign Investment Company Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>PFIC Status of the Company</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company were to constitute a &ldquo;passive
foreign investment company&rdquo; under the meaning of Section 1297 of the Code (a &ldquo;<B>PFIC</B>&rdquo;, as defined below)
for any year during a U.S. Holder&rsquo;s holding period, then certain potentially adverse rules may affect the U.S. federal income
tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares. The Company believes
that it was classified as a PFIC during the tax year ended December 31, 2017, and based on current business plans and financial
expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future tax years. No opinion
of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or is currently planned
to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application
of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation
will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and,
as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the
IRS will not challenge any determination made by the Company (or any subsidiary of the Company) concerning its PFIC status. Each
U.S. Holder should consult its own tax advisors regarding the PFIC status of the Company and each subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In any year in which the Company is classified
as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations
and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in
an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding
the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company generally will be a PFIC if,
for a tax year, (a) 75% or more of the gross income of the Company is passive income (the &ldquo;<B>PFIC income test</B>&rdquo;)
or (b) 50% or more of the value of the Company&rsquo;s assets either produce passive income or are held for the production of passive
income, based on the quarterly average of the fair market value of such assets (the &ldquo;<B>PFIC asset test</B>&rdquo;). &ldquo;Gross
income&rdquo; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental
or outside operations or sources, and &ldquo;passive income&rdquo; generally includes, for example, dividends, interest, certain
rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the PFIC income test and
PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding
shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other
corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes
of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &ldquo;passive income&rdquo;
does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain &ldquo;related
persons&rdquo; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable
to the income of such related person that is not passive income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under certain attribution rules, if the
Company is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Company&rsquo;s direct or indirect
equity interest in any company that is also a PFIC (a &lsquo;&lsquo;<B>Subsidiary PFIC</B>&rsquo;&rsquo;), and will generally be
subject to U.S. federal income tax on their proportionate share of (a) any &ldquo;excess distributions,&rdquo; as described below,
on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Company
or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. In addition, U.S. Holders
may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition
of Common Shares. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions
are received and no redemptions or other dispositions of Common Shares are made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Default PFIC Rules
Under Section 1291 of the Code</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is a PFIC for any tax year
during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition,
ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Company
and each Subsidiary PFIC, if any, as a &ldquo;qualified electing fund&rdquo; or &ldquo;QEF&rdquo; under Section 1295 of the Code
(a &ldquo;<B>QEF Election</B>&rdquo;) or makes a mark-to-market election under Section 1296 of the Code (a &ldquo;<B>Mark-to-Market
Election</B>&rdquo;). A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in
this summary as a &ldquo;<B>Non-Electing U.S. Holder</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Non-Electing U.S. Holder will be subject
to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable
disposition of Common Shares and (b) any &ldquo;excess distribution&rdquo; received on the Common Shares. A distribution generally
will be an &ldquo;excess distribution&rdquo; to the extent that such distribution (together with all other distributions received
in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S.
Holder&rsquo;s holding period for the Common Shares, if shorter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Section 1291 of the Code, any gain
recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary
PFIC), and any &ldquo;excess distribution&rdquo; received on Common Shares or with respect to the stock of a Subsidiary PFIC, must
be ratably allocated to each day in a Non-Electing U.S. Holder&rsquo;s holding period for the respective Common Shares. The amount
of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and
to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates).
The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary
income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such
tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest
paid as &ldquo;personal interest,&rdquo; which is not deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is a PFIC for any tax year
during which a Non-Electing U.S. Holder holds Common Shares, the Company will continue to be treated as a PFIC with respect to
such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years. A Non-Electing
U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section
1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which
the Company was a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>QEF Election</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a timely and effective
QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the
rules of Section 1291 of the Code discussed above with respect to its Common Shares. A U.S. Holder that makes a timely and effective
QEF Election will be subject to U.S. federal income tax on such U.S. Holder&rsquo;s pro rata share of (a) the net capital gain
of the Company, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Company,
which will be taxed as ordinary income to such U.S. Holder. Generally, &ldquo;net capital gain&rdquo; is the excess of (a) net
long-term capital gain over (b) net short-term capital loss, and &ldquo;ordinary earnings&rdquo; are the excess of (a) &ldquo;earnings
and profits&rdquo; over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax
on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to
such U.S. Holder by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders
that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made
a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current
U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest
paid will be treated as &ldquo;personal interest,&rdquo; which is not deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a timely and effective
QEF Election with respect to the Company generally (a) may receive a tax-free distribution from the Company to the extent that
such distribution represents &ldquo;earnings and profits&rdquo; of the Company that were previously included in income by the U.S.
Holder because of such QEF Election and (b) will adjust such U.S. Holder&rsquo;s tax basis in the Common Shares to reflect the
amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes
a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The procedure for making a QEF Election,
and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF
Election will be treated as &ldquo;timely&rdquo; if such QEF Election is made for the first year in the U.S. Holder&rsquo;s holding
period for the Common Shares in which the Company was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate
QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does
not make a timely and effective QEF Election for the first year in the U.S. Holder&rsquo;s holding period for the Common Shares,
the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain
requirements and makes a &ldquo;purging&rdquo; election to recognize gain (which will be taxed under the rules of Section 1291
of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective.
If a U.S. Holder makes a QEF Election but does not make a &ldquo;purging&rdquo; election to recognize gain as discussed in the
preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under
the rules of Section 1291 discussed above with respect to its Common Shares. If a U.S. Holder owns PFIC stock indirectly through
another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary
PFIC for the QEF rules to apply to both PFICs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A QEF Election will apply to the tax year
for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated
or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the
Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years
in which the Company is not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election
will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which
the Company qualifies as a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company: (a) will make available to
U.S. Holders, upon their written request, information as to its status as a PFIC and the PFIC status of any subsidiary in which
the Company owns more than 50% of such subsidiary&rsquo;s total aggregate voting power and (b) for each year in which the Company
is a PFIC, provide to a U.S. Holder, upon written request, such information and documentation that a U.S. Holder making a QEF Election
with respect to the Company and such more than 50% owned subsidiary which constitutes a PFIC is reasonably required to obtain for
U.S. federal income tax purposes. The Company may elect to provide such information on its website. With respect to any Subsidiary
PFIC in which the Company owns 50% or less of the aggregate voting power, upon the written request of a U.S. Holder acquiring Common
Shares, the Company will request that such Subsidiary PFIC provide such U.S. Holder with the information that such U.S. Holder
requires to report under the QEF rules; provided, however, the Company can provide no assurances that such Subsidiary PFIC will
provide such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder makes a QEF Election by attaching
a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return.
However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S.
Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of
the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Mark-to-Market Election</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder may make a Mark-to-Market
Election only if the Common Shares are marketable stock. The Common Shares generally will be &ldquo;marketable stock&rdquo; if
the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange
Commission, (b) the national market system established pursuant to section 11A of the Securities and Exchange Act of 1934, or (c)
a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is
located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements,
and meets other requirements and the laws of the country in which such foreign exchange is located, together with the rules of
such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively
promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally
will be &ldquo;regularly traded&rdquo; for any calendar year during which such stock is traded, other than in de minimis quantities,
on at least 15 days during each calendar quarter. Provided that the Common Shares are &ldquo;regularly traded&rdquo; as described
in the preceding sentence, the Common Shares are expected to be marketable stock. However, each U.S. Holder should consult its
own tax advisor in this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a Mark-to-Market
Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above
with respect to such Common Shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax
year of such U.S. Holder&rsquo;s holding period for the Common Shares for which the Company is a PFIC and such U.S. Holder has
not made a timely QEF Election, the rules of Section&nbsp;1291 of the Code discussed above will apply to certain dispositions of,
and distributions on, the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a Mark-to-Market
Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any,
of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&rsquo;s adjusted
tax basis in such Common Shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal
to the excess, if any, of (a) such U.S. Holder&rsquo;s adjusted tax basis in the Common Shares, over (b) the fair market value
of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market
Election for prior tax years).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that makes a Mark-to-Market
Election generally also will adjust such U.S. Holder&rsquo;s tax basis in the Common Shares to reflect the amount included in gross
income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition
of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed
the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over
(b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Losses that exceed this limitation
are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder makes a Mark-to-Market Election
by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies
to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to
be &ldquo;marketable stock&rdquo; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax
advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although a U.S. Holder may be eligible
to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of
any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election
will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to
deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Other PFIC Rules</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Section 1291(f) of the Code, the
IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a
timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred
(e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to
a U.S. Holder may vary based on the manner in which Common Shares are transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain additional adverse rules may apply
with respect to a U.S. Holder if the Company is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example,
under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided
in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special rules also apply to the amount
of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes
paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules
relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should
consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The PFIC rules are complex,
and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal
income tax consequences of the acquisition, ownership, and disposition of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Rules Applicable to the Ownership and Disposition
of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion describes the
general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules
described above under the heading &ldquo;Passive Foreign Investment Company Rules.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Distributions on Common Shares</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder that receives a distribution,
including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution
in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of
the current and accumulated &ldquo;earnings and profits&rdquo; of the Company, as computed for U.S. federal income tax purposes.
A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Company is a PFIC for the tax year of such
distribution or the preceding tax year. To the extent that a distribution exceeds the current and accumulated &ldquo;earnings and
profits&rdquo; of the Company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S.
Holder's tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares. (See &ldquo;<I>Sale
or Other Taxable Disposition of Common Shares</I>&rdquo; below). However, the Company may not maintain the calculations of its
earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution
by the Company with respect to the Common Shares will constitute ordinary dividend income. Dividends received on Common Shares
by corporate U.S. Holders generally will not be eligible for the &ldquo;dividends received deduction.&rdquo; Subject to applicable
limitations and provided the Company is eligible for the benefits of the Canada-U.S. Tax Convention or the Common Shares are readily
tradable on a United States securities market, dividends paid by the Company to non-corporate U.S. Holders, including individuals,
generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain
holding period and other conditions are satisfied, including that the Company not be classified as a PFIC in the tax year of distribution
or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding
the application of such rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Sale or Other Taxable Disposition of
Common Shares</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the sale or other taxable disposition
of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the
U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder's tax basis in such
Common Shares sold or otherwise disposed of. A U.S. Holder&rsquo;s tax basis in Common Shares generally will be such holder&rsquo;s
U.S. dollar cost for such Common Shares. Gain or loss recognized on such sale or other disposition generally will be long-term
capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preferential tax rates currently apply
to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates
for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations
under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><U>Additional Tax on Passive
Income</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Certain U.S. Holders
that are individuals, estates or trusts (other than trusts that are exempt from tax) will be subject to a 3.8% tax on all or a
portion of their &ldquo;net investment income,&rdquo; which includes dividends on the Common Shares and net gains from the disposition
of the Common Shares. Further, excess distributions treated as dividends, gains treated as excess distributions under the PFIC
rules discussed above, and mark-to-market inclusions and deductions are all included in the calculation of net investment income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><BR>
Treasury Regulations provide, subject to the election described in the following paragraph, that solely for purposes of this additional
tax, that distributions of previously taxed income will be treated as dividends and included in net investment income subject to
the additional 3.8% tax. Additionally, to determine the amount of any capital gain from the sale or other taxable disposition of
Common Shares that will be subject to the additional tax on net investment income, a U.S. Holder who has made a QEF Election will
be required to recalculate its basis in the Common Shares excluding QEF basis adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Alternatively, a U.S.
Holder may make an election which will be effective with respect to all interests in a PFIC for which a QEF Election has been made
and which is held in that year or acquired in future years. Under this election, a U.S. Holder pays the additional 3.8% tax on
QEF income inclusions and on gains calculated after giving effect to related tax basis adjustments. U.S. Holders that are individuals,
estates or trusts should consult their own tax advisors regarding the applicability of this tax to any of their income or gains
in respect of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><BR>
<U>Receipt of Foreign Currency</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of any distribution paid to
a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal
to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether
such foreign currency is converted into U.S. dollars at that time). A U.S. Holder will have a basis in the foreign currency equal
to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after
the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally
will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method
of tax accounting. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences
of receiving, owning, and disposing of foreign currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Foreign Tax Credit</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC rules discussed above,
a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common
Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian
income tax. Generally, a credit will reduce a U.S. Holder&rsquo;s U.S. federal income tax liability on a dollar-for-dollar basis,
whereas a deduction will reduce a U.S. Holder&rsquo;s income that is subject to U.S. federal income tax. This election is made
on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during
a year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Complex limitations apply to the foreign
tax credit, including the general limitation that the credit cannot exceed the proportionate share of a U.S. Holder&rsquo;s U.S.
federal income tax liability that such U.S. Holder&rsquo;s &ldquo;foreign source&rdquo; taxable income bears to such U.S. Holder&rsquo;s
worldwide taxable income. In applying this limitation, a U.S. Holder&rsquo;s various items of income and deduction must be classified,
under complex rules, as either &ldquo;foreign source&rdquo; or &ldquo;U.S. source.&rdquo; Generally, dividends paid by a foreign
corporation should be treated as foreign source for this purpose, and gains recognized on the sale of stock of a foreign corporation
by a U.S. Holder should be treated as U.S. source for this purpose, except as otherwise provided in an applicable income tax treaty,
and if an election is properly made under the Code. However, and subject to certain exceptions, a portion of the dividends paid
by a foreign corporation will be treated as U.S. source income for U.S. foreign tax credit purposes, in proportion to its U.S.
source earnings and profits, if U.S. persons own, directly or indirectly, 50 percent or more of the voting power or value of the
foreign corporation&rsquo;s shares. The amount of a distribution with respect to the Common Shares that is treated as a &ldquo;dividend&rdquo;
may be lower for U.S. federal income tax purposes than it is for Canadian federal income tax purposes, resulting in a reduced foreign
tax credit allowance to a U.S. Holder. In addition, this limitation is calculated separately with respect to specific categories
of income. The foreign tax credit rules are complex, and each U.S. Holder should consult its own U.S. tax advisors regarding the
foreign tax credit rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Backup Withholding and Information Reporting</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under U.S. federal income tax law, certain
categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation.
For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold
certain specified foreign financial assets in excess of certain thresholds. The definition of specified foreign financial assets
includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained
by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment
that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to
these reporting requirements unless their Common Shares are held in an account at certain financial institutions. Penalties for
failure to file certain of these information returns are substantial. U.S. Holders should consult with their own tax advisors regarding
the requirements of filing information returns, including the requirement to file an IRS Form 8938.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments made within the U.S., or by a
U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares
will generally be subject to information reporting and backup withholding tax, at the rate of 24%, if a U.S. Holder (a) fails to
furnish such U.S. Holder&rsquo;s correct U.S. taxpayer identification number (generally on Form W-9), (b) furnishes an incorrect
U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report
items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished
its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup
withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding
rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed
as a credit against a U.S. Holder&rsquo;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes
required information to the IRS in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discussion of reporting requirements
set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder.
A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess
a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting
requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE ABOVE SUMMARY IS NOT INTENDED TO
CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP,
AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO
THEM IN THEIR OWN PARTICULAR CIRCUMSTANCES.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_018"></A>WHERE YOU CAN FIND
ADDITIONAL INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has filed with the SEC
a registration statement on Form F-10 relating to, among other securities, the Common Shares. This Prospectus Supplement and the
Prospectus, both of which constitute a part of the registration statement, do not contain all of the information contained in
the registration statement, certain items of which are contained in the exhibits to the registration statement as permitted by
the rules and regulations of the SEC. See &ldquo;<I>Documents Filed as Part of the Registration Statement</I>&rdquo; in this Prospectus
Supplement and the Prospectus. Statements contained in this Prospectus Supplement, the Prospectus or a document incorporated by
reference in the Prospectus about the contents of any contract, agreement or other documents referred to are not necessarily complete,
and in each instance you should refer to the exhibits to the registration statement for a more complete description of the matter
involved. The registration statement, and the items of information omitted from this Prospectus Supplement and the Prospectus
but contained in the registration statement, will be available on EDGAR (<U>www.sec.gov/edgar.shtml</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is subject to the information
requirements of the U.S.&nbsp;Exchange Act and applicable Canadian securities legislation and, in accordance therewith, files and
furnishes annual and quarterly financial information and material change reports, business acquisition reports and other material
with the securities commission or similar regulatory authority in each of the provinces of Canada and with the SEC. Under MJDS
adopted by the United States and Canada, documents and other information that the Corporation files with the SEC may be prepared
in accordance with the disclosure requirements of Canada, which are different from those of the United States. As a foreign private
issuer within the meaning of rules made under the U.S.&nbsp;Exchange Act, the Corporation is exempt from the rules under the U.S.&nbsp;Exchange
Act prescribing the furnishing and content of proxy statements, and the Corporation&rsquo;s officers, directors and principal shareholders
are exempt from the reporting and shortswing profit recovery provisions contained in Section&nbsp;16 of the U.S.&nbsp;Exchange
Act. In addition, the Corporation is not required to publish financial statements as promptly as United States companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may read any document that the Corporation
has filed with the SEC on EDGAR at www.sec.gov/edgar.shtml and such information can also be inspected and copies ordered at the
SEC&rsquo;s public reference room in Washington, D.C. You may also obtain copies of those documents from the public reference
room of the SEC at 100&nbsp;F&nbsp;Street,&nbsp;N.E., Washington, D.C.&nbsp;20549 by paying a fee. You should call the SEC at
1-800-SEC-0330 or access its website at www.sec.gov for further information about the public reference rooms. You may read and
download any public document that the Corporation has filed with the Canadian securities regulatory authorities under the Corporation&rsquo;s
profile on SEDAR (<U>www.sedar.com</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_019"></A>LEGAL MATTERS AND
INTEREST OF EXPERTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The auditors of the Corporation are Ernst
 &amp; Young LLP, Chartered Accountants, 1000, 440 &ndash; 2<SUP>nd</SUP> Avenue S.W., Calgary, Alberta, T2P 5E9. Ernst &amp; Young
LLP is independent of the Corporation in accordance with the Rules of Professional Conduct as outlined by the Institute of Chartered
Accountants of Alberta. Ernst &amp; Young LLP is registered with the U.S. Public Corporation Accounting Oversight Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain legal matters relating to the Offering
will be passed upon on our behalf by McCarthy Tetrault LLP with respect to certain Canadian legal matters and by Dorsey &amp; Whitney
LLP with respect to certain U.S. legal matters and on behalf of the Investor by K&amp;L Gates LLP with respect to certain U.S.
legal matters. As at the date hereof, the partners and associates of each of McCarthy Tetrault LLP beneficially own, directly or
indirectly, less than 1% of the Common Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="sa_020"></A>AGENT FOR SERVICE
OF PROCESS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano, William G. Rice
and Bernd R. Seizinger are directors of the Corporation who reside outside of Canada. Messrs. Pisano, Rice and Seizinger have
appointed the Corporation, at its principal place of business, as agent for service of process. Purchasers are advised that it
may not be possible for investors to enforce judgments obtained in Canada against any person that resides outside of Canada, even
if the party has appointed an agent for service of process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>BASE SHELF PROSPECTUS</B><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>May 4, 2018</B><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv503751_logo.jpg" ALT="" STYLE="height: 105px; width: 240px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Cdn.$150,000,000</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Shares</B><BR>
<B>Subscription Receipts</B><BR>
<B>Warrants</B><BR>
<B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. (the &ldquo;<B>Corporation</B>&rdquo;,
 &ldquo;<B>Oncolytics</B>&rdquo;, &ldquo;<B>we</B>&rdquo;, &ldquo;<B>our</B>&rdquo; or &ldquo;<B>us</B>&rdquo;) may from time to
time offer and issue the following securities: (i) common shares in the capital of the Corporation (&ldquo;<B>Common Shares</B>&rdquo;);
(ii) subscription receipts of the Corporation exchangeable for Common Shares and/or other securities of the Corporation (&ldquo;<B>Subscription
Receipts</B>&rdquo;); (iii) warrants exercisable to acquire Common Shares and/or other securities of the Corporation (&ldquo;<B>Warrants</B>&rdquo;);
and (iv) securities comprised of more than one of Common Shares, Subscription Receipts and/or Warrants offered together as a unit
(&ldquo;<B>Units</B>&rdquo;), or any combination thereof, up to an aggregate offering price of $150,000,000 (or the equivalent
thereof, at the date of issue, in any other currency or currencies, as the case may be) at any time during the 25-month period
that this short form base shelf prospectus (including any amendments hereto, the &ldquo;<B>Prospectus</B>&rdquo;) remains valid.
The Common Shares, Subscription Receipts, Warrants and Units (collectively, the &ldquo;<B>Securities</B>&rdquo;) offered hereby
may be offered separately or together, in separate series, in amounts, at prices and on terms to be set forth in one or more prospectus
supplements (collectively or individually, as the case may be, &ldquo;<B>Prospectus Supplements</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The specific terms of any offering of Securities
will be set forth in the applicable Prospectus Supplement and may include, without limitation, where applicable: (i) in the case
of Common Shares, the number of Common Shares being offered, the offering price (in the event the offering is a fixed price distribution),
the manner of determining the offering price(s) (in the event the offering is not a fixed price distribution) and any other specific
terms; (ii) in the case of Subscription Receipts, the number of Subscription Receipts being offered, the offering price, the terms,
conditions and procedures for the exchange of the Subscription Receipts into or for Common Shares and/or other securities of the
Corporation and any other specific terms; (iii) in the case of Warrants, the number of such Warrants offered, the offering price,
the terms, conditions and procedures for the exercise of such Warrants into or for Common Shares and/or other securities of the
Corporation and any other specific terms; and (iv) in the case of Units, the number of Units being offered, the offering price,
the terms of the Common Shares, Subscription Receipts and/or Warrants, as the case may be, underlying the Units, and any other
specific terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This offering is made by a Canadian issuer
that is permitted, under a multijurisdictional disclosure system adopted by the United States and Canada (&ldquo;<B>MJDS</B>&rdquo;),
to prepare this Prospectus in accordance with Canadian disclosure requirements. Prospective investors in the United States should
be aware that such requirements are different from those of the United States. Financial statements included or incorporated by
reference herein have been prepared in accordance with International Financial Reporting Standards (&ldquo;<B>IFRS</B>&rdquo;)
as issued by the International Accounting Standards Board (&ldquo;<B>IASB</B>&rdquo;) and may not be comparable to financial statements
of United States companies. Such financial statements are subject to Canadian generally accepted auditing standards and auditor
independence standards, in addition to the standards of the Public Company Accounting Oversight Board (United States) and the United
States Securities and Exchange Commission (&ldquo;<B>SEC</B>&rdquo;) independence standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective investors should be aware that
the acquisition of the securities described herein may have tax consequences both in the United States and in Canada. Such consequences
for investors who are resident in, or citizens of, the United States may not be described fully herein. Prospective investors should
read the tax discussion contained in the applicable Prospectus Supplement with respect to a particular offering of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The enforcement by investors of civil
liabilities under the United States federal securities laws may be affected adversely by the fact that the Corporation is incorporated
under the laws of Alberta, Canada, that the majority of its officers and directors are residents of Canada, that many of the experts
named in the registration statement are not residents of the United States, and that a substantial portion of the assets of the
Corporation and said persons are located outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE SEC NOR ANY STATE OR CANADIAN
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED THE SECURITIES OFFERED HEREBY OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR
COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any investment in Securities involves
significant risks that should be carefully considered by prospective investors before purchasing Securities. The risks outlined
in this Prospectus and in the documents incorporated by reference herein, including the applicable Prospectus Supplement, should
be carefully reviewed and considered by prospective investors in connection with any investment in Securities. See &ldquo;<I>Risk
Factors</I>&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All shelf information permitted under applicable
securities legislation to be omitted from this Prospectus including, without limitation, the information disclosed in the specific
terms of any offering of Securities, as discussed above, will be contained in one or more Prospectus Supplements that will be delivered
to purchasers together with this Prospectus, except in cases where an exemption from such delivery requirements has been obtained.
Each Prospectus Supplement will be incorporated by reference into this Prospectus for the purposes of securities legislation as
of the date of such Prospectus Supplement and only for the purposes of the distribution of the Securities to which that Prospectus
Supplement pertains.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the Securities to or through
one or more underwriters or dealers purchasing as principals and may also sell the Securities to one or more purchasers directly,
through applicable statutory exemptions, or through one or more agents designated by us from time to time. The Securities may be
sold from time to time in one or more transactions at fixed prices or not at fixed prices, such as market prices prevailing at
the time of sale, prices related to such prevailing market prices or prices to be negotiated with purchasers, which prices may
vary as between purchasers and during the period of distribution of the Securities. The Prospectus Supplement relating to a particular
offering of Securities will identify each underwriter, dealer or agent engaged in connection with the offering and sale of such
Securities, as well as the method of distribution and the terms of the offering of such Securities, including the initial offering
price (in the event the offering is a fixed price distribution), the manner of determining the offering price(s) (in the event
the offering is not a fixed price distribution), the net proceeds to us and, to the extent applicable, any fees, discounts or any
other compensation payable to underwriters, dealers or agents and any other material terms. See &ldquo;<I>Plan of Distribution</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with any offering of the
Securities other than an &ldquo;at-the-market distribution&rdquo; (as defined under applicable Canadian legislation) (unless otherwise
specified in the relevant Prospectus Supplement), the underwriters or agents may over-allot or effect transactions that stabilize
or maintain the market price of the offered Securities at a level above that which might otherwise prevail on the open market.
Such transactions, if commenced, may be interrupted or discontinued at any time. See &ldquo;<I>Plan of Distribution</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No underwriter or dealer involved in an
 &ldquo;at-the-market distribution&rdquo; under this Prospectus, no affiliate of such an underwriter or dealer and no person or
company acting jointly or in concert with such underwriter or dealer will over-allot securities in connection with such distribution
or effect any other transactions that are intended to stabilize or maintain the market price of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Owning the Securities may subject you to
tax consequences. This Prospectus and any applicable Prospectus Supplement may not describe the tax consequences fully. You should
read the tax discussion in any applicable Prospectus Supplement and consult with your own tax advisor with respect to your own
particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unless otherwise specified in the applicable
Prospectus Supplement, the Subscription Receipts, Warrants and Units will not be listed on any securities exchange. There is no
market through which these securities may be sold and purchasers may not be able to resell such securities purchased under this
Prospectus. This may affect the pricing of such securities in the secondary market, the transparency and availability of trading
prices, the liquidity of such securities, and the extent of issuer regulation. See &ldquo;<I>Forward-Looking Statements</I>&rdquo;
and &ldquo;<I>Risk Factors</I>&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our outstanding securities are listed
for trading on the Toronto Stock Exchange (&ldquo;<B>TSX</B>&rdquo;) under the trading symbol &ldquo;<B>ONC</B>&rdquo; and are
quoted for trading on the OTCQX Best Market (&ldquo;<B>OTCQX</B>&rdquo;) under the trading symbol &ldquo;<B>ONCYF</B>&rdquo;.
On May 3, 2018, the closing price of our Common Shares on the TSX was $0.63 per Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano, William G. Rice and
Bernd R. Seizinger are directors of the Corporation who reside outside of Canada. Messrs. Pisano, Rice and Seizinger have appointed
the Corporation, at its principal place of business, as agent for service of process. Purchasers are advised that it may not be
possible for investors to enforce judgments obtained in Canada against any person that resides outside of Canada, even if the party
has appointed an agent for service of process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No underwriter, agent or dealer has
been involved in the preparation of this Prospectus or performed any review of the contents of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
4000, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>TABLE
OF CONTENTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Page</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">ABOUT
    THIS PROSPECTUS AND OTHER MATTERS</A></FONT></TD>
    <TD STYLE="width: 10%; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">4</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">FORWARD-LOOKING
    STATEMENTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">4</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">6</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">DOCUMENTS
    INCORPORATED BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">6</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">DOCUMENTS
    FILED AS PART OF THE REGISTRATION STATEMENT</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">7</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">ADDITIONAL
    INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">THE
    CORPORATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">BUSINESS
    OF THE CORPORATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">8</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">CONSOLIDATED
    CAPITALIZATION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">DESCRIPTION
    OF SHARE CAPITAL</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">9</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">DESCRIPTION
    OF SUBSCRIPTION RECEIPTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">10</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">11</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">12</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015">PLAN
    OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_015">12</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016">PRIOR
    SALES</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_016">13</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017">TRADING
    PRICE AND VOLUME</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_017">13</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018">CERTAIN
    INCOME TAX CONSIDERATIONS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_018">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019">LEGAL
    MATTERS AND INTEREST OF EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_019">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020">AUDITORS,
    TRANSFER AGENT AND REGISTRAR</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_020">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">AGENT
    FOR SERVICE OF PROCESS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_021">14</A></FONT></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Arial, Helvetica, Sans-Serif; text-transform: uppercase; background-color: White">
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022">ENFORCEABILITY
    OF CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</A></FONT></TD>
    <TD STYLE="text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_022">14</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_001"></A>ABOUT THIS PROSPECTUS
AND OTHER MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and any Prospectus Supplement,
unless otherwise indicated, references to &ldquo;<B>we</B>&rdquo;, &ldquo;<B>us</B>&rdquo;, &ldquo;<B>our</B>&rdquo;, &ldquo;<B>issuer</B>&rdquo;
 &ldquo;<B>Oncolytics</B>&rdquo; or the &ldquo;<B>Corporation</B>&rdquo; are to Oncolytics Biotech Inc., including, where the context
requires, its subsidiaries and affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Prospectus and in any Prospectus
Supplement, unless otherwise specified or the context otherwise requires, all references to &ldquo;<B>dollars</B>&rdquo; or &ldquo;<B>$</B>&rdquo;
are to Canadian dollars and all references to &ldquo;<B>US$</B>&rdquo; are to United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all financial
information included and incorporated by reference in this Prospectus and any Prospectus Supplement is determined using IFRS as
issued by IASB and adopted by the Accounting Standards Board of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus provides you with a general
description of the Securities that the Corporation may offer. Each time the Corporation sells Securities under this Prospectus,
the Corporation will file and deliver, except in cases where an exemption from such delivery requirement has been obtained, a Prospectus
Supplement that will contain specific information about the terms of that offering of Securities. The Prospectus Supplement also
may add, update or change information contained in this Prospectus. Before investing, investors should read both this Prospectus
and any applicable Prospectus Supplement together with additional information described under the heading &ldquo;<I>Documents Incorporated
by Reference</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained in or incorporated by reference in this Prospectus or any applicable Prospectus Supplement. The Corporation has not authorized
anyone to provide you with different or additional information. The Corporation is not making an offer of these Securities in any
jurisdiction where the offer is not permitted by law. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_002"></A>FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Prospectus and the documents incorporated
by reference herein contain certain statements relating to future events or the Corporation&rsquo;s future performance which constitute
forward-looking statements within the meaning of applicable Canadian securities laws and within the meaning of the United States
Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of the Corporation, or industry results, to be
materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their
underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies;
the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of
regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry
and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future
performance. Forward-looking statements generally, but not always, are identified by the words &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
 &ldquo;believes,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects&rdquo;, &ldquo;potential&rdquo;, &ldquo;possible&rdquo;
and similar expressions, or that events or conditions &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;could&rdquo; or &ldquo;should&rdquo;
occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements in this
Prospectus are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control,
including without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to all of our products, including REOLYSIN&reg;, being in the research and development
stage and requiring further development and testing before they can be marketed commercially;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks inherent in pharmaceutical research and development;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to timing and possible delays in our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to some of our clinical trials being conducted in, and subject to the laws of foreign
countries;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our pharmaceutical products being subject to intense regulatory approval processes
in the United States and other foreign jurisdictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to being subject to government manufacturing and testing regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the extremely competitive biotechnology industry and our competition with larger
companies with greater resources;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our reliance on patents and proprietary rights to protect our technology;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential product liability claims;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our limited manufacturing experience and reliance on third parties to commercially
manufacture our products, if and when developed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our new products not being accepted by the medical community or consumers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our technologies becoming obsolete;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on third party relationships for research and clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our license, development, supply and distribution agreement with Adlai Nortye
Biopharma Co. Ltd.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our lack of operating revenues and history of losses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">uncertainty regarding our ability to obtain third-party reimbursement for the costs of our product;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to other third-party arrangements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our ability to obtain additional financing to fund future research and development
of our products and to meet ongoing capital requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to potential increases in the cost of director and officer liability insurance;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our dependence on key employees and collaborators;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to Barbados law, including those relating to the enforcement of judgments obtained
in Canada or the United States;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the effect of changes in the law on our corporate structure;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to expenses in foreign currencies and our exposure to foreign currency exchange rate
fluctuations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to fluctuations in interest rates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to information technology systems; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our Common Shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This list is not exhaustive of the factors
that may affect any of the Corporation&rsquo;s forward-looking statements. Some of the important risks and uncertainties that could
affect forward-looking statements are described further under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our Annual Report.
If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may
vary materially from those expected, estimated or projected. Forward-looking statements in this document are not a prediction of
future events or circumstances, and those future events or circumstances may not occur. Given these uncertainties, users of the
information included herein, including investors and prospective investors, are cautioned not to place undue reliance on such forward-looking
statements. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to forward-looking statements. The Corporation does not undertake any obligation
to publicly update or revise any forward-looking statements other than as required under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prospective investors should carefully
consider the information contained under the heading &ldquo;<I>Risk Factors</I>&rdquo; in our Annual Report and all other information
included in or incorporated by reference in this Prospectus before making investment decisions with regard to the Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_003"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in the Securities involves
a high degree of risk. Prospective investors should note that there is no market through which the Subscription Receipts, Warrants
or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased under this
Prospectus. This may affect the pricing of these securities in the secondary market, the transparency and availability of trading
prices, the liquidity of the securities, and the extent of issuer regulation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prospective investors should consider carefully
the risks described in the documents incorporated by reference in this Prospectus (including in subsequently filed documents incorporated
by reference) and those described in any Prospectus Supplement before purchasing the Securities offered hereby. Discussions of
certain risks affecting the Corporation in connection with its business are provided under the heading &ldquo;<I>Risk Factors</I>&rdquo;
in our Annual Report filed with the various securities regulatory authorities, which is incorporated by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_004"></A>DOCUMENTS INCORPORATED
BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information has been incorporated
by reference in this Prospectus from documents filed with securities commissions or similar authorities in Canada. </B>Copies
of the documents incorporated herein by reference may be obtained on request without charge from our Corporate Secretary at 210,
1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7 telephone (403)&nbsp;670-7377, and are available electronically
under the Corporation&rsquo;s profile on SEDAR (www.sedar.com) and on EDGAR (www.sec.gov/edgar.shtml).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed the following documents with
the securities commissions or similar regulatory authorities in certain of the provinces of Canada and such documents are specifically
incorporated by reference in, and form an integral part of, this Prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(a)</FONT></TD><TD STYLE="text-align: justify">our annual report on Form 20-F (&ldquo;<B>Annual Report</B>&rdquo;) dated March 19, 2018, for the
year ended December 31, 2017 (filed in Canada with the Canadian securities regulatory authorities in lieu of an annual information
form);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(b)</FONT></TD><TD STYLE="text-align: justify">our management information circular dated March 27, 2018 relating to the annual general meeting
of shareholders to be held on May 3, 2018;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(c)</FONT></TD><TD STYLE="text-align: justify">our audited consolidated financial statements, together with the notes thereto, as at December&nbsp;31,
2017 and 2016, which comprise the consolidated statements of financial position as at December&nbsp;31, 2017 and 2016, and the
consolidated statements of loss and comprehensive loss, changes in equity, and cash flows for the years ended December&nbsp;31,
2017 and 2016, together with the independent auditors&rsquo; report thereon; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">(d)</FONT></TD><TD STYLE="text-align: justify">our management&rsquo;s discussion and analysis of financial condition and results of operations
dated March&nbsp;8, 2018, for the year ended December&nbsp;31, 2017.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any documents of the type required by National
Instrument 44-101 - <I>Short Form Prospectus Distributions</I> to be incorporated by reference in a short form prospectus, including
any annual information form, annual report on Form 20-F, comparative annual consolidated financial statements and the auditors&rsquo;
report thereon, comparative interim consolidated financial statements, management&rsquo;s discussion and analysis of financial
condition and results of operations, material change report (except a confidential material change report), business acquisition
report and information circular, if filed by us with the securities commissions or similar authorities in Canada after the date
of this Prospectus and prior to the date which is 25 months from the date of this Prospectus, shall be deemed to be incorporated
by reference in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, to the extent that any document
or information incorporated by reference into this Prospectus is included in any report filed with or furnished to the SEC pursuant
to the United States Securities Exchange Act of 1934, as amended (the &ldquo;<B>U.S. Exchange Act</B>&rdquo;), after the date of
this Prospectus, such document or information shall be deemed to be incorporated by reference as an exhibit to the registration
statement of which this Prospectus forms a part (in the case of documents or information deemed furnished on Form 6-K or Form 8-K,
only to the extent specifically stated therein)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Any statement contained in this Prospectus
or in a document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for
the purposes of this Prospectus to the extent that a statement contained in this Prospectus or in any other subsequently filed
document which also is, or is deemed to be, incorporated by reference into this Prospectus modifies or supersedes that statement.
The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other
information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement shall
not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation,
an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary
to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute part of this Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon a new annual information form and
the related audited annual financial statements and management&rsquo;s discussion and analysis being filed by us with the applicable
securities regulatory authorities during the term of this Prospectus, the previous annual information form, the previous audited
annual financial statements and related management&rsquo;s discussion and analysis, all unaudited interim financial statements
and related management&rsquo;s discussion and analysis, material change reports and business acquisition reports filed prior to
the commencement of our financial year in which the new annual information form and the related audited annual financial statements
and management&rsquo;s discussion and analysis are filed shall be deemed no longer to be incorporated into this Prospectus for
purposes of future offers and sales of Securities hereunder. Upon new interim financial statements and related management&rsquo;s
discussion and analysis being filed by us with the applicable securities regulatory authorities during the term of this Prospectus,
all interim financial statements and related management&rsquo;s discussion and analysis filed prior to the new interim consolidated
financial statements and related management&rsquo;s discussion and analysis shall be deemed no longer to be incorporated into this
Prospectus for purposes of future offers and sales of Securities hereunder. Upon a new information circular relating to an annual
general meeting of holders of Common Shares being filed by us with the applicable securities regulatory authorities during the
term of this Prospectus, the information circular for the preceding annual general meeting of holders of Common Shares shall be
deemed no longer to be incorporated into this Prospectus for purposes of future offers and sales of Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any &ldquo;template version&rdquo;
of any &ldquo;marketing materials&rdquo; (as such terms are defined in National Instrument 41-101) pertaining to a distribution
of Securities will be filed under the Corporation&rsquo;s profile on SEDAR (www.sedar.com). In the event that such marketing materials
are filed subsequent to the date of filing of the applicable prospectus supplement pertaining to the distribution of the Securities
to which such marketing materials relates and prior to the termination of such distribution, such filed versions of the marketing
materials will be deemed to be incorporated by reference into the Prospectus for purposes of future offers and sales of Securities
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One or more Prospectus Supplements containing
the specific variable terms for an issue of the Securities and other information in relation to such Securities will be delivered
to purchasers of such Securities together with this Prospectus, except in cases where an exemption from such delivery requirement
has been obtained, and will be deemed to be incorporated by reference into this Prospectus as of the date of the Prospectus Supplement
solely for the purposes of the offering of the Securities covered by any such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_005"></A>DOCUMENTS FILED AS
PART OF THE REGISTRATION STATEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documents have been or
will be filed with the SEC as part of the registration statement of which this Prospectus forms a part: (i)&nbsp;the documents
set out under the heading &ldquo;<I>Documents Incorporated by Reference</I>&rdquo;; (ii)&nbsp;the consents of the Corporation&rsquo;s
auditor and legal counsel; and (iii)&nbsp;the powers of attorney from the directors and certain officers of the Corporation. A
copy of the form of warrant indenture, unit indenture or subscription receipt agreement, as applicable, will be filed by post-effective
amendment or by incorporation by reference to documents filed or furnished with the SEC under the U.S.&nbsp;Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_006"></A>ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation has filed with the
SEC a registration statement on Form F-10 relating to the Securities. This Prospectus, which constitutes a part of the registration
statement, does not contain all of the information contained in the registration statement, certain items of which are contained
in the exhibits to the registration statement as permitted by the rules and regulations of the SEC. See &ldquo;<I>Documents Filed
as Part of the Registration Statement</I>&rdquo;. Statements included or incorporated by reference in this Prospectus about the
contents of any contract, agreement or other documents referred to are not necessarily complete, and in each instance you should
refer to the exhibits to the registration statement for a more complete description of the matter involved. The registration statement,
and the items of information omitted from this Prospectus but contained in the registration statement, will be available on EDGAR
(www.sec.gov/edgar.shtml). Each time we sell Securities under the registration statement, we will provide a Prospectus Supplement
that will contain specific information about the terms of that offering. The Prospectus Supplement may also add to, update or
change information contained in this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is subject to the information
requirements of the U.S.&nbsp;Exchange Act and applicable Canadian securities legislation and, in accordance therewith, files
and furnishes annual and quarterly financial information and material change reports, business acquisition reports and other material
with the securities commission or similar regulatory authority in each of the provinces of Canada and with the SEC. Under MJDS
adopted by the United States and Canada, documents and other information that the Corporation files with the SEC may be prepared
in accordance with the disclosure requirements of Canada, which are different from those of the United States. As a foreign private
issuer within the meaning of rules made under the U.S.&nbsp;Exchange Act, the Corporation is exempt from the rules under the U.S.&nbsp;Exchange
Act prescribing the furnishing and content of proxy statements, and the Corporation&rsquo;s officers, directors and principal
shareholders are exempt from the reporting and shortswing profit recovery provisions contained in Section&nbsp;16 of the U.S.&nbsp;Exchange
Act. In addition, the Corporation is not required to publish financial statements as promptly as United States companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">You may read any
document that the Corporation has filed with the SEC on EDGAR at www.sec.gov/edgar.shtml and such information can also be inspected
and copies ordered at the SEC&rsquo;s public reference room in Washington, D.C. You may also obtain copies of those documents
from the public reference room of the SEC at 100&nbsp;F&nbsp;Street,&nbsp;N.E., Washington, D.C.&nbsp;20549 by paying a fee. You
should call the SEC at 1-800-SEC-0330 or access its website at www.sec.gov for further information about the public reference
rooms. You may read and download any public document that the Corporation has filed with the Canadian securities regulatory authorities
under the Corporation&rsquo;s profile on SEDAR (www.sedar.com).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_007"></A>THE CORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oncolytics Biotech Inc. was incorporated
pursuant to the ABCA on April&nbsp;2, 1998 as 779738 Alberta Ltd. On April&nbsp;8, 1998, we amended our articles of incorporation
(the &ldquo;<B>Articles</B>&rdquo;) and changed our name to Oncolytics Biotech Inc. On July&nbsp;29, 1999, we further amended our
Articles by removing the private company restrictions included therein and subdivided the 2,222,222 Common Shares issued and outstanding
into 6,750,000 Common Shares. On February&nbsp;9, 2007, we further amended our Articles to permit shareholder meetings to be held
at any place in Alberta or at any other location as determined by our board of directors (the &ldquo;<B>Board</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have two material operating subsidiaries:
Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (US) Inc., a Delaware corporation. Oncolytics Biotech (Barbados) Inc.
is incorporated pursuant to the laws of Barbados and is a wholly-owned direct subsidiary of the Corporation. Oncolytics Biotech
(U.S.) Inc. is incorporated pursuant to the laws of Delaware and is a wholly-owned direct subsidiary or Oncolytics Biotech (Barbados)
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head office and principal place of
business is located at 210, 1167 Kensington Crescent N.W., Calgary, Alberta, T2N&nbsp;1X7. Our registered office is located at
4000, 421&nbsp;-&nbsp;7<SUP>th</SUP>&nbsp;Avenue S.W., Calgary, Alberta, T2P&nbsp;4K9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_008"></A>BUSINESS OF THE CORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">General</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in April of 1998, Oncolytics
Biotech Inc. has been a development stage company and we have focused our research and development efforts on the development of
REOLYSIN (pelareorep), a systemically administered immuno-oncology (&ldquo;<B>I-O</B>&rdquo;) viral agent with the potential to
treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses
as we continue research and development efforts. We do not expect to generate significant revenues until, if and when, pelareorep
becomes commercially viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our potential product for human use, pelareorep,
an unmodified reovirus, is a first in class systemically administered I-O viral agent for the treatment of solid tumors and hematological
malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further information regarding the business
of the Corporation is contained in the Annual Report under the heading &ldquo;<I>Item 4 &ndash; Information on the Company</I>&rdquo;,
which document is incorporated by reference in this Prospectus. See &ldquo;Documents Incorporated by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Recent Developments</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2018, the Corporation received
approval from the holders of Common Shares to amend the Articles to effect the consolidation of the issued and outstanding Common
Shares on the basis of a consolidation ratio to be selected by the Board, in its sole discretion, provided that the ratio may be
not less than two (2), and not more than fifteen (15), pre-consolidation Common Shares for each one post-consolidation Common Share,
such amendment to become effective at a date in the future to be determined by the Board when the Board considers it to be in the
best interests of the Corporation, but in any event no later than February 22, 2019, subject to approval of the Toronto Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_009"></A>CONSOLIDATED CAPITALIZATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has been no material change in the
share and loan capital of the Corporation on a consolidated basis since December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_010"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The use of proceeds from the issue and
sale of specific Securities pursuant to this Prospectus will be described in the Prospectus Supplement relating to the issuance
and sale of such Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_011"></A>DESCRIPTION OF SHARE
CAPITAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Authorized Capital</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of an unlimited
number of Common Shares. The following is a summary of the provisions attached to our Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Common Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our Common Shares are entitled
to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining
property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are
no pre-emptive, conversion or redemption rights attached to such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at the date hereof, we have 142,325,222
Common Shares issued and outstanding. After giving effect to the exercise of all outstanding options to acquire Common Shares and
all outstanding share awards granted under the Corporation&rsquo;s Incentive Share Award Plan, we would have 154,164,330 Common
Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Common Share Purchase
Warrants</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, we have 16,445,000
Common Share purchase warrants (the &ldquo;<B>2017 Warrants</B>&rdquo;) issued and outstanding. Each 2017 Warrant entitles the
holder to purchase one Common Share until June 1, 2022, at an exercise price of $0.95. The 2017 Warrants are subject to acceleration
if the volume weighted average price of the Common Shares equals or exceeds $2.50 for a period of 15 consecutive trading dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as of the date hereof, the
Corporation has outstanding Common Share purchase warrants as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a Common Share purchase warrant (the &ldquo;<B>First Adlai Warrant</B>&rdquo;) exercisable by the
holder thereof until May 14, 2018 to purchase such number of Common Shares as is calculated by dividing US$2,000,000 by the Exercise
Price (as defined below); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a Common Share purchase warrant (the &ldquo;<B>Second Adlai Warrant</B>&rdquo;) exercisable by
the holder thereof until November 14, 2020 to purchase such number of Common Shares as is calculated by dividing US$6,000,000 by
the Exercise Price.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the First Adlai Warrant
and the Second Adlai Warrant, the term &ldquo;<B>Exercise Price</B>&rdquo; means an amount equal to 120% of the volume weighted
average trading price of the Common Shares on the TSX (or, if the Common Shares begin trading on The NASDAQ Capital Market, on
The NASDAQ Capital Market as of the date such trading commences) for the five trading days immediately preceding the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The First Adlai Warrant is subject to a
right to call by the Corporation upon the later of: (i) May 14, 2018; and (ii) the date of the enrollment of the first patient
in a Phase III Study related to pelareorep. The Second Adlai Warrant is subject to a right to call by the Corporation upon the
date of the enrollment of the fiftieth (50<SUP>th</SUP>) patient in a Phase III Study related to pelareorep.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_012"></A>DESCRIPTION OF SUBSCRIPTION
RECEIPTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Subscription Receipts sets forth certain general terms and provisions of Subscription Receipts in respect of which a Prospectus
Supplement may be filed. The particular terms and provisions of Subscription Receipts offered by any Prospectus Supplement, and
the extent to which the general terms and provisions described below may apply thereto, will be described in the Prospectus Supplement
filed in respect of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subscription Receipts may be offered
separately or in combination with one or more other Securities. The Subscription Receipts will be issued under a subscription
receipt agreement (the&nbsp;&rdquo;<B>Subscription Receipt Agreement</B>&rdquo;). A copy of the Subscription Receipt Agreement
will be filed by us with the applicable securities regulatory authorities after it has been entered into by us and will be available
electronically under the Corporation&rsquo;s profile on SEDAR (www.sedar.com) and, if applicable, we will file with the SEC via
EDGAR (www.sec.gov/edgar.shtml) as exhibits to the registration statement of which this Prospectus is a part, or will incorporate
by reference from a Report of Foreign Private Issuer on Form 6-K that we file with the SEC, any Subscription Agreement describing
the terms and conditions of such Subscription Receipts that we are offering before the issuance of such Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Subscription Receipt Agreement,
original purchasers of Subscription Receipts will have a contractual right of rescission against the Corporation, following the
issuance of the underlying Common Share or other securities to such purchasers upon the surrender or deemed surrender of the Subscription
Receipts, to receive the amount paid for the Subscription Receipts in the event that this Prospectus or a Prospectus Supplement,
and any amendment thereto, contains a misrepresentation or is not delivered to such purchaser, provided such remedy for rescission
is exercised within 180&nbsp;days from the closing date of the offering of Subscription Receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Subscription Receipts described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Subscription Receipts offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Subscription Receipts will be offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Subscription Receipts
are denominated;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the procedures for the exchange of the Subscription Receipts into Common Shares or other securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Common Shares or other securities that may be obtained upon exercise of each Subscription
Receipt;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of any other Securities with which the Subscription Receipts will be
offered, if any, and the number of Subscription Receipts that will be offered with each Security;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the terms applicable to the gross proceeds from the sale of the Subscription Receipts plus any
interest earned thereon;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the material Canadian tax consequences of owning such Subscription Receipts; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Subscription
Receipts.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Subscription Receipts that are not within the options and parameters set forth in this
Prospectus. In addition, to the extent that any particular terms of the Subscription Receipts described in a Prospectus Supplement
differ from any of the terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be
deemed to have been superseded by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_013"></A>DESCRIPTION OF WARRANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of the terms
of Warrants sets forth certain general terms and provisions of Warrants in respect of which a Prospectus Supplement may be filed.
The particular terms and provisions of Warrants offered by any Prospectus Supplement, and the extent to which the general terms
and provisions described below may apply thereto, will be described in the Prospectus Supplement filed in respect of such Warrants.
Warrants may be offered separately or in combination with one or more other Securities. If applicable, we will file with the SEC
as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by reference from a current report
on Form 6-K that we file with the SEC, any warrant indenture or form of warrant describing the terms and conditions of such Warrants
that we are offering before the issuance of such Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The description of general terms and provisions
of Warrants described in any Prospectus Supplement will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and aggregate number of Warrants offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Warrants will be offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Warrants are denominated;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of the Common Shares that may be acquired upon exercise of the Warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date on which the right to exercise the Warrants will commence and the date on which the right
will expire;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the number of Common Shares that may be purchased upon exercise of each Warrant and the price at
which and currency or currencies in which that amount of securities may be purchased upon exercise of each Warrant;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and terms of any Securities with which the Warrants will be offered, if any, and
the number of the Warrants that will be offered with each Security;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date or dates, if any, on or after which the Warrants and the related Securities will be transferable
separately;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the minimum or maximum amount, if any, of Warrants that may be exercised at any one time;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether the Warrants will be subject to redemption or call, and, if so, the terms of such redemption
or call provisions; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Warrants.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Warrants that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Warrants described in a Prospectus Supplement differ from any of the
terms described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_014"></A>DESCRIPTION OF UNITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue Units comprised of one or
more of the other Securities described in this Prospectus in any combination. Each Unit will be issued so that the holder of the
Unit is also the holder of each Security included in the Unit. Thus, the holder of a Unit will have the rights and obligations
of a holder of each included Security. The unit agreement, if any, under which a Unit is issued may provide that the Securities
comprising the Unit may not be held or transferred separately, at any time or at any time before a specified date. If applicable,
we will file with the SEC as exhibits to the registration statement of which this Prospectus is a part, or will incorporate by
reference from a current report on Form 6-K that we file with the SEC, any unit agreement describing the terms and conditions of
such Units that we are offering before the issuance of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms and provisions of
Units offered by any Prospectus Supplement, and the extent to which the general terms and provisions described below may apply
to them, will be described in the Prospectus Supplement filed in respect of such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The particular terms of each issue of Units
will be described in the related Prospectus Supplement. This description will include, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the designation and aggregate number of Units offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the price at which the Units will be offered;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if other than Canadian dollars, the currency or currency unit in which the Units are denominated;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the terms of the Units and of the Securities comprising the Units, including whether and under
what circumstances those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any provisions for the issuance, payment, settlement, transfer or exchange of the Units or of the
Securities comprising the Units; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any other material terms, conditions and rights (or limitations on such rights) of the Units.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to set forth in a
Prospectus Supplement specific terms of the Units that are not within the options and parameters set forth in this Prospectus.
In addition, to the extent that any particular terms of the Units described in a Prospectus Supplement differ from any of the terms
described in this Prospectus, the description of such terms set forth in this Prospectus shall be deemed to have been superseded
by the description of such differing terms set forth in such Prospectus Supplement with respect to such Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_015"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell the Securities to or through
one or more underwriters or dealers purchasing as principals and we may also sell the Securities to one or more purchasers directly,
through applicable statutory exemptions, or through one or more agents designated from time to time. The Securities may be sold
from time to time in one or more transactions at fixed prices or not at fixed prices, such as market prices prevailing at the time
of sale, prices related to such prevailing market prices or prices to be negotiated with purchasers, which prices may vary as between
purchasers and during the period of distribution of the Securities. The Prospectus Supplement relating to a particular offering
and sale of Securities will identify each underwriter, dealer or agent engaged in connection with the offering and sale of such
Securities, as well as the method of distribution and the terms of the offering and sale of such Securities, including the initial
offering price (in the event the offering is a fixed price distribution), the manner of determining the offering price(s) (in the
event the offering is not a fixed price distribution), the net proceeds to us and, to the extent applicable, any fees, discounts
or any other compensation payable to underwriters, dealers or agents and any other material terms. Only underwriters so named in
the Prospectus Supplement are deemed to be underwriters in connection with the Securities offered and sold thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the underwriters purchase Securities
from us as principal, the Securities will be acquired by the underwriters for their own account and may be resold from time to
time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined
at the time of sale, at market prices prevailing at the time of sale or at prices related to such prevailing market prices. The
obligations of the underwriters to purchase such Securities as principal will be subject to certain conditions precedent, and the
underwriters will be obligated to purchase all the Securities offered and sold by the Prospectus Supplement if any of such Securities
are purchased. Any public offering price and any discounts or concessions allowed or re-allowed or paid to underwriters, dealers
or agents may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities may be sold from time to
time in one or more transactions at a fixed price or prices which may be changed or at market prices prevailing at the time of
sale, at prices related to such prevailing market prices or at negotiated prices, including sales in transactions that are deemed
to be &ldquo;at-the-market distributions&rdquo; as defined in National Instrument 44-102 &ndash; <I>Shelf Distributions</I>, including
sales made directly on the TSX or other existing trading markets for the Common Shares. In the event that we elect to pursue an
 &ldquo;at-the-market distribution&rdquo; in Canada, we will apply for the required exemptive relief from the applicable securities
commissions or similar regulatory authorities in Canada. The prices at which the Securities may be offered may vary as between
purchasers and during the period of distribution. If, in connection with the offering of Securities at a fixed price or prices,
the underwriters have made a bona fide effort to sell all of the Securities at the initial offering price fixed in the applicable
Prospectus Supplement, the public offering price may be decreased and thereafter further changed, from time to time, to an amount
not greater than the initial public offering price fixed in such Prospectus Supplement, in which case the compensation realized
by the underwriters will be decreased by the amount that the aggregate price paid by purchasers for the Securities is less than
the gross proceeds paid to us by the underwriters. Any such reduction to the public offering price will not affect the net proceeds
received by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities may also be sold directly
by us, pursuant to applicable statutory exemptions, at such prices and upon such terms as agreed to by us and the purchaser or
through one or more agents designated by us from time to time. Any agent involved in the offering and sale of the Securities in
respect of which this Prospectus is delivered will be named, and any commissions payable by us to such agent will be set forth,
in the Prospectus Supplement. Unless otherwise indicated in the Prospectus Supplement, any agent would be acting on a best efforts
basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may agree to pay the underwriters a
commission for various services relating to the issue and sale of any Securities offered hereby. Any such commission will be paid
out of our general funds. Underwriters, dealers and agents who participate in the distribution of the Securities may be entitled
under agreements to be entered into with us to indemnification by us against certain liabilities under securities legislation,
or to contribution with respect to payments which such underwriters, dealers or agents may be required to make in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any offering of Subscription Receipts,
Warrants or Units will be a new issue of securities with no established trading market. Unless otherwise specified in the applicable
Prospectus Supplement, the Subscription Receipts, Warrants or Units will not be listed on any securities exchange. Certain dealers
may make a market in these Securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. No assurance can be given that any dealer will make a market in these Securities or as to the liquidity of the trading
market, if any, for these Securities. See &ldquo;<I>Risk Factors</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in a Prospectus
Supplement, in connection with any offering of the Securities, the underwriters or agents may over-allot or effect transactions
which stabilize or maintain the market price of the Securities offered at a higher level than that which might exist in the open
market. Such transactions, if commenced, may be interrupted or discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_016"></A>PRIOR SALES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding prior sales of Securities
will be provided as required in a Prospectus Supplement with respect to the issuance of Securities pursuant to such Prospectus
Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_017"></A>TRADING PRICE AND
VOLUME</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information regarding trading price and
volume of the Securities will be provided as required for all of the Corporation&rsquo;s issued and outstanding Securities that
are listed on any securities exchange, as applicable, in each Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_018"></A>CERTAIN INCOME TAX
CONSIDERATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The applicable Prospectus Supplement may
describe certain Canadian federal income tax consequences which may be applicable to a purchaser of Securities offered thereunder,
and may also include a discussion of certain United States federal income tax consequences to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_019"></A>LEGAL MATTERS AND
INTEREST OF EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in the Prospectus
Supplement relating to an offering and sale of Securities, certain legal matters relating to such offering and sale of Securities
will be passed upon on behalf of the Corporation by McCarthy T&eacute;trault LLP with respect to matters of Canadian law and Dorsey
 &amp; Whitney LLP, with respect to matters of U.S. law. In addition, certain legal matters in connection with an offering and sale
of Securities will be passed upon for any underwriters, dealers or agents by counsel to be designated at the time of such offering
and sale by such underwriters, dealers or agents with respect to matters of Canadian and, if applicable, United States or other
foreign law. As at the date hereof, the partners and associates of McCarthy T&eacute;trault LLP, as a group, own less than 1% of
the outstanding securities of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_020"></A>AUDITORS, TRANSFER
AGENT AND REGISTRAR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The auditor of the Corporation is Ernst
 &amp; Young LLP, Chartered Professional Accountants, Calgary, Alberta. Ernst &amp; Young LLP has confirmed that it is independent
of the Corporation within the meaning of the relevant rules and related interpretations prescribed by the relevant professional
bodies in Canada and applicable legislation or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for the
Common Shares is Computershare Trust Company of Canada at its principal offices located in Calgary, Alberta and Toronto, Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_021"></A>AGENT FOR SERVICE
OF PROCESS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Messrs. Wayne Pisano, William G. Rice and
Bernd R. Seizinger are directors of the Corporation who reside outside of Canada. Messrs. Pisano, Rice and Seizinger have appointed
the Corporation, at its principal place of business, as agent for service of process. Purchasers are advised that it may not be
possible for investors to enforce judgments obtained in Canada against any person that resides outside of Canada, even if the party
has appointed an agent for service of process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_022"></A>ENFORCEABILITY OF
CIVIL LIABILITIES AGAINST NON-U.S. PERSONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation is a corporation existing
under the <I>Business Corporations Act</I> (Alberta). Most of the Corporation&rsquo;s directors and officers, and some or all
of the experts named in this Prospectus, are residents of Canada or otherwise reside outside the United States, and all or a substantial
portion of their assets, and substantially all of the Corporation&rsquo;s assets, are located outside the United States. The Corporation
has appointed an agent for service of process in the United States, but it may be difficult for holders of Securities who reside
in the United States to effect service within the United States upon those directors, officers and experts who are not residents
of the United States. It may also be difficult for holders of Securities who reside in the United States to realize in the United
States upon judgments of courts of the United States predicated upon the Corporation&rsquo;s civil liability and the civil liability
of its directors, officers and experts under the United States federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation filed with the SEC,
concurrently with its registration statement on Form&nbsp;F-10 of which this Prospectus is a part, an appointment of agent for
service of process on Form&nbsp;F-X. Under the Form&nbsp;F-X, the Corporation appointed DL&nbsp;Services Inc. as its agent for
service of process in the United States in connection with any investigation or administrative proceeding conducted by the SEC,
and any civil suit or action brought against or involving the Corporation in a United States court arising out of or related to
or concerning the offering of the Securities under this Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tv503751_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv503751_img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!10'E P$1  (1 0,1 ?_$ -\   (" P$! 0$
M      <(!08#! D" 0 * 0  !P$! 0$              0,$!08' @@)"A
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M[3(LC:1W'(+[8]/IN+$]?3X2?GH0.4W^%/<(A$Y+DBM]LAO]MPDG]8LOC_\
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MZVC<$[';Y?'<:$"0Z(W6I#+X3X]SL #NG;J/7UT($AT194$A">IV"1_H&^A
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M00)-E*AUD4AJ7.?CQ-WT,)1T)_?IC?J^DVO:!<;RXE*E&0D<,<NGYXD?*("
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MK<IAM^D"AJ_,!$O](>5KENN#O@*I=A$)+>^W?-HB;"9CJF\M<K6_):445F3
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MP1O?:M((=!5W*V)W(V]=S\/PT4<QF<=0ME2$DA21_F _9\]"!%*>D.)F; ]
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M_P"7!D1W._\ Q?88Z1U_-_A+GI W^6V^A]<5TD?W./V#_N3!5_K6?_%S0?\
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MX8SFYWQ]2S;DA'E1C.1U889SZ^B+#69US!GM1=2:)B/28A <0EFUNXJ8[4J
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M'':_BG'\IF4TR'F]:B@N+=_'<<SMN._%^[KGZ62M-["$!2$N1IZ'FP^DJ0L
MG5:WUL,5*Y4Z%G'("-C]*O693=G%)?VJ=-4L3&E04,>L0NV8<N9=.PTX#D&+
MMUSOW-6+/(E"U0]9,4,NRFU3+=(IU575OIG6KCLEU#8<D=C8)Z'57H]DN4]8
M&DI*2!CJ.GYXMVYMWMW2W(<H%MJ\72!\D0G&4W&HU[,7DRL7==30S?Y=5FD"
MSGX@S>J=0['=R*#3K:L'H349;I01NCSI;[_HWTINRH>HK0W26T!1#IF1EJPF
M)Q8]I7.W/5&K=#:C0<E(20@K.KL'#KBS768<;4&>9U!QEC)W./LRK*FI78X%
M:/XQ=Q9$=^ENYLK$I<Y;TF/C\N_K2S]G(&RX)2V/R)WB7[3<*^VMO590)2/O
MB8A>VWMJW[B6N@: MX2K22)*E^SG/JB.N;-KF7E"KKZN%_)M>^BDQ2"JZ#DJ
MQCUE36AAF1<OCPR9EQ.#*GEJ2!Y'' GT(U/VI3-KH35+4DM 8Z3J/<(2N/-W
M=>PY2E"","'%!L^P*SB!Y.XQ@\;91CD6993[>GMH%7DCD6QJ1CF0PZE^R7&L
M:^TJ42Y:J^>N&RLL*"]PV4_/76W;G4W=HK<&&.<1&ZMKKM-=RFN7-.)DH&&L
MH*#C#D+D*;B["N.)?'%IC^7JAY-QWB-C5W/%.+U\J)D.,VF7RW&&(S]JJ-3N
M5[R@%2>V0HK6H*1L\??0R]RESU9Y?3%6*C5L*?IR-"/"9F1FG.0X]L2,#E+B
MC*J/"46$'C3&J>IR?EA5?C<S$D-KJ7[HOS.-)MQ-KJN5)M,.AJ2TW.0N3VD;
M+6TO;;2C:DN^X1.(C2^ZP:IG%H+"<\9GJCY:9K[<SAV3XE:/TTC)KDXM)B3\
M9IU,<4,<H,8ADD&PR]['4P8KDS%X$XU[91%1&2Y/=,KL4TE2"<\91P$59&6'
M; GQ_..%8$]MW['$LA^\?X,IY3E]03+Y%=C,7CYJ#R5(IOO6/%"VR*.IPG9;
MJ% >,M@=NA#ANDN:<6 DGK4!!@5D7MC9P?#H=1CN&3GX\^B<L$7EE8MY"AZ+
M<..W$J<NNQ.7>2*F;7(2VEUZ>\TVT1XF"0="%5IOQ:Y3B4:1/[PA8/<,G!+?
M,E3N/7J5ZED5,1$E&/P8D2J8L6O('F6'X,*IK[93;7:ER4U"B%QP'R(*]U$X
M=T[80W)?\[C"WPJ[LDHW3LA*E$@ ^OS ! )Z:[2TM>*8EF&F"GQB+6W%*-R@
M#L()3\#MTZ=OPUPH%'O0BXRDG\N/CK2BA?T]2.G3XZX"@H80FTTM!\44U<5]
M$@K*"$+44)VZ]=R?0>GIKJ'A(*9<8N;<)*X03L2H)!._P&V_KOHHXC+C&&7F
M1VXK<?IK&\L/$N48=7$=F2$PV!WORUI:!2W%8&W>LD)25#?UT<)J=0A6E6!B
M?NJ.36F566<5^NL8Y\;\">RY%EQG.A\<AAY*%,.%L]_:H));^L;IZZ$!U:43
M0HC5**E.Q"WQVT:B7=>_5RUL5T\1I8#;Z8-K#CV-?,6@*5V1I<"2AU"CZH.^
MA#,2USF)1/LJ6TE2P4CQ)45C?N*4(;2Z5+2D*+;:4.#=2NU*3T)!(!$/6WVD
MB1.,HCGY:VW5H<(03L2%=.U!4M!<4"D%"$*0=R>GRWT([;*7?<(CZ[)8#"OK
M&_C[BD?F"/XNSFQV[DJ+"MMMR=O30CFITL"3A$Y=,24[%L@BT=3D\JL?C8_=
M/R8E3:/J90S828I4)#45DN_>.ADC8K#?CWZ=V^ND@$XPQ:!<.M/NQ7%,K24+
M.P4AY'8HD?0L+^(^ *3UWU'ONN)7(91)(.E,CG*&4KO:S:YCP_1<D85EU9?W
MDM4_]2P1<9RO=A)KYBV6V(-PXHUWZH%#S&.\!Y4J 2"2!K/=R>H-7MF^HM'C
M\HH@$@$Y]D*(96Y[LN^ -'QNTI9,JNO*Z;76L12D2J^=$<C3V'=SNER&I"7$
MG;KN$!OKT.M+H+G17!"'*!P>)(,E>$SXX'KAM5_TLT.YRX8_-$?*9[72$=JT
M!&Y43^7O21U)V*5(_P QU(KIF%F53[W"6.,-&F'7AS6Y:!G,RAEO;W[H\D]N
ML.PB8EBV)6;.12H_\X)R,7DQ&15$4D_ISK4:?'@USO79$IEI;J#UZGIJ@;LV
M/;;ZF=Q4EML8@@B<QB.R'1IS4IT4HFZ!QP$^V.W/ V2X=[J^-+N\S7VRP.*.
M/*),2=(SIZ=2.&RFIDM*;JZ&C74(>GU\K8E:Y2QLE7=^8G6![H?HZ$_#6:IQ
M50<) $B?;#5DW*@JPS5B3YP &([Q!.MLEQ+(:G^1*>CK*/%#,7!6K[MF$N34
MH);2FMAM!#3@+2AZ_2GJ-0EDV1<7%HJWE3<*IY\)X1>U4]2FE\S5S"R,ACAP
MB3>PFLQW&F\%BY!&3&KY<5QV/"_M5DDH=6KH?X2$QE@/))/D Z:]?[*J6[90
M(I'"I2E )4",)=,9;<JUPU3O+U&2#P@XG(4PL>CXK2$/MI#"8I2PA+:41'VF
MV5@IWW"VD$A/Q3JVWFCM%#3^;M\C4J!F")8RBD6RH775JD+*IX_3"0<UXG8Q
M<J3;-IF.Q41V7HU?5N-)G2+"65M/H;4\M(2MS;Z$J]3Z:S9+E%>F5V^Y)'.
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ME60F\3XUK)'TR1BV-JE+9L7&""J(]D<R8J4L*Z_6V@@$$ZZ^:-BVM;.13AX
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M(6$F)E%6]@C-7*QO'XM%5P"PB+E3+D]"I$6N^Z2^''U)6E?<(=T-OK]<P3*
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MH4&&_*BJBWC,63+8"PX[&@.OSZNLD+<66E+2%@@CTZ#SK>]FOUU0'[=X6=.
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M^ V]0!MH0]( 2)1N/2F0TM7<2"-QL#\O7_-H">4<1!QI#2GU.H6D@=Q[E$)
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M' XQO<MTF,XWE<&GJHM379%%IHJ<^QK'9\^VHL9R=UX.NT]59V/]XF-PH#J
MX=SW.;GIZ:/:3]QO5*7JQ*0X0< "!+L)/?.''J3060;L9M&VE+6RRF3I60I6
MH'W9@"0.,\,8%Z+R;B%W"NZA_P"UM*V0),1UQIMY'8HJ0II^,\A33T>7&6II
MYM0*'6UJ2H$'5FJ&V!2F@69)XRP,5NLYUCNK;M,VAAV0\: 03+KF8O>.<V.2
M\QQFYR>JK8U'C-?95V/4>+X[30:+%4SHC\>/-I:%UERH=DP);PF>*0"E2D@
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M9O)QFIEYO2XE<1VHN2-VM929%F<C#H4V-*\L1&2M5<R(0XIIHQEM]B_(5-K
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M=/P .^CAER'-4\)1)_</(!W'1)Z_4/3?I_9_'1QP?"9&'9A/J_Y;^2.?VO\
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MI* TZ3%PO-27:8)5[VH0$\IIW)2U/(2H $;=4G<C?N)*=TJ!/RU-N.MU&+&
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MH*Q!(GV2CG5[%?<7BLBPR7A_G"Y9K*W-LIG<BXEF4]8$G&N6Y*B)RI,M;J'
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MF%J1C\A4M#SI*F@XXI2$C8#=6XVZ?5^_6<J833**&S@3/#I.)C2PE$@0!E!
M4\8U<6T]0AH@@C96_H"!KGMCJ E,+RK(]R-@M87T'YE=1N0 /JV'KHM*1D!
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MQID229G.'24A TC**O+?<[E*^GJ/RD?0>A/4;_,:*.H@(=0F;-2^]VMJ*C\
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MU"04H3])/3X=3_IWT($;5BR[T ]2D ;'XC8G_-HQG!B'!AMK_P"7-D0VZ_\
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MZ2?Z;'WM45S%F5IER6U(*=E*0CNZ#8;@'K\3IZA?/&H0A%LD1X#:"H,^1_\
MMK(V (!]#O\ (:0@X'TZ"Y/DI<4GJA2@CU] =A^SIHX"/YA]D23M>E$-$=22
M%NC8;;[=1_K:$2:):/9%'MHJ:UAQ0*4*4A:1ON05$^GT@D?YAH&(^HXQ2J"W
M=$T!"AVH=6C<_%:'/$KMWZD=_311Q!BBXC<9C)JJ7'X4RSO;>7'KZROKT>6P
MFVD@[-08J "L*<4.IZ) W.XT<<+JDTHUJRCKCP?P#6>W[%GH4AQJYY&OXK*L
MSR!DER/6MN=KRL+HI"_XJHD<_2^^K\ZTD?#?0,5.OJO,N:TG"<%*57>1&T9!
MZIVV([4D]I[E  $ *5UV^>N8CIF!5<P3]PMM:?XH^CXE/7\=MMM' B'5AT:6
MVK^'N5IW/3X_'X>F^A'2<Q%4?X^9<6HH9/TJ[=B DDG;T!_,-=90^3+E]T5&
MYPAHN-L1X_FE)<4VMAAG9U'3N"W#W=J6B/59(2G^T0.N@ ! F8!N<\A<?<<>
M:G?D-9+E,5"U+QZHDM2HL&2M)+3E]8I4J.DQU]?$TLK^&_KHHD$(+V'"%PF9
MQ.SAX2[AYLI:_P#,H3*"(4$=W>&6&R>Y6Y'Q/[]%A$@F@*&-1Z3!JS&#C=YC
M'#,%BAXWPE>54]]-R3,&ZZQ99;=H<OOJ>'+E)KS;SFV55E<RI;:(ZEJ5W';;
M1X2AI33YZDJPD,.O*)ZMX'QR9A$O)VGK[.WUVN65\?)<"$,8IA\/'(D2=!N<
MEC7,1BP<K<C7+#K:5B&L1H:T[$JT(=JKJFGP:22(GLM]LF&8G>2X>.3K?*[:
MPXTY>B1X5I03W:NTLZ[C]BXI\DQ25+J*J.Y8PK.:H-,Q'9X"4=WF_L@1%+KJ
MBHJ EP&44;D:C:Q7/+.KJJ;]*JGZC%Y\1AN.ZB"^U*QZ XF7%4M.R6Y*UJ.X
MW[E D@:*+"T)-@13/MQ$<4\XIOL5U5NO8;^NQW]!TT(4B2A7L9M7A92VE*@H
MJ4@]RCT^6C&<'QAQX=@G_E^Y#)V5_P#%YAP_+UZ\4YT?GZ=/73CC%65_[2G_
M )*O]R(*_P#6#?<8]W=&4,^3MX;P\=WP -]E0.^D#PB,V<ZIJPJ0C+7] CF)
M-^VFI^I 2X$I.R $['Y'H=%%T0XHA,Y8I$4!U'ADN]JEG;X$[_$]/0?+0AS(
M:9\8TIM[(<+<4,A"=P@K4G<D*&QZ;]#TT(:.O+09"4134EW[Y#>X">B/3X [
M=>OPVT(6:45^]&:_JU/!M3+R5)4E1=2/S#M'P(/3H?EH0JH &0BLLSEPB&4-
MN.;;@'??;_1HHYB<<><?:2E:NSO;*BU_;.WHH*/38[_+X:$"!/E"B.G<>UH;
MCJ?QW!^8T($7_ I:'E,1TA("F$J)VW^H_CU]=M"!%BRR,V4*<!4%EM70$=N^
MQ W&WRT($!J/C<A<IJ2I(6P'-P%>GE)*D_NZ]='"2F4+Q,X),=B55M>=H(:[
MOS%"3ZGT Z_EZ:$*(2$91X&8*V<C25!7>.T!(VW_ ,YZC0CHDG./#%.N7(3(
M4D$D]Z#ML0/]._71$3@#W@>L0;N)*3!?YVH&^2,BO,6PEMU;EY;8_$E3KLQ&
MTEQROA-PG6)#9LU'Q+<!(:0HJVW&D7Z=JH 2Z)RA6MJ*FUN"X6U1\S+CBGNP
M^>.K#GNY]K5)70J:CE9JSCM+#:K:+'J;"4Q8E9!:"5!MI,NXC>22N2CO=D*2
M7)#GUD[';3QEBF/OB79A&>O6ZLK,25+5TJQSBI_\</"3LA,:JPWE^^>2'7D)
M9K<<CJ0TPEYQYW=B7/?8:VW)6$A22>A&DJ]RST+?-.I3_0H@IEPPE],/;?9;
MXRP:=C *)G@9^PQ$1O?OQLI0>J^(,S=6WV!EZPRJGBN(4@AU"G!'JY3J5-.'
M<=2K36F>17M%QG2E? # 2AW0[>^%ZG*\K*59DG&9RX9148U[QYE.;Y%SWG6!
MR.[-[9FPX\X[3(^YC6UFVRQ6O7\X);CO2Z]V<$-AHA*2X2H[[Z>T2G0X4U(&
MCJ$5B_W2G:\""0GMAY+_  S,L*H<9L[.]&(Y!>5S$N_I*BH:=CXI7V#P4VF8
M"7U1'&V7/H[ $@[=--+@P'G-"YR/1%/M=Q4Q5"H2HE0Z<1&#+K[VK\:U.>V\
MED3<NY%K*9O([QZ\4Q>V]I!>\<6WB09I2['4[(<5NVCOW4H[;)V .DV_2TSP
MJFBX7)#,S'=*-!N6[KG>K8+>^&A3"8\*=*LNF9^:(;!^*<5SFC5>W6:M2<*L
MV5AS&9D)N1+BNHW0TU,N'FBV G;?\=NO3TF>0HN<U7O2E%-I&G*8\FG6L\1,
MSQ$"?D^FXQXX#&!X_4P5O3H<VMQ[-Z=:;!^I1DKK(MZ=58Y(>AQF)8;\BGF_
M(=R=MAT%0NUDIGW-=45C&>!E]!BZ6OU W!8D\NZACR8RD@A4NLZC\T!*@X"O
MIM@Q/D64)K%TO.(79+=4'GNQ906FFYG9XEMH  W4=AJMWR_KHOY824=8G],:
MWLY%MWFWS:%9;3^L?](8>EPSA;'&]["%0WDM@@NJMY9F +!Z+0R2&D*5\0.X
M:H%TW!<JH<^B,F92]O&+TY8+-:%<AUPN5^<PH:9'(2EGTXP ><,[X'B,6%55
MXV:K(8#)>5)IB8M6"X"6#*4/X"E/ ;);!"C\-)4>[;FED-%8YJ"%9<1[<HE+
M;Z?W&_.$-)(IUI()3@989'IA5<']]+_![\>L8Q-F34W3ZX]LNQEKDS)L.<%1
M;!A,%*7!%:D05*04M[!:3]0.N+%NY36Z$WZK<4*T*& ,D9C-/VQ>KCZ,T3VU
ME;?>+RV%)/O+!5,@Y'3T]4/;PSSU0X[Q?>XO<56/6^)X];9%?QYDR76HGXEB
M5ZTS*QVKCTKS8M;-NW7,5';6WVH:[#W$#6G>J-U?NE6;G;I'#'##+MCRSZ*;
M)1:=[/\ I\' +\@&849C#'+LSB69Y&X^H:AO+,2XBEJ778_)A5]A-AK318K!
M"G)'W$&LD]Y=5)"RZI0"R4] >W6 .;D;:I32OJ5YG62<<,8])4_IE>%7;E/J
MIPUSBE7AQP,L#/NPA#,O]TW,,^Q6U4M27(S,IY8#$:2V)34GJR(Q::[&!N/[
M) _#7%"W>*\A5*5$>]QX1NU3L79.TZ'SMU<22692*A+692X=L4Z?R-EMJY&N
M[:J?ERO#NY&>?2+-2FE][[)D,,I=4V=CT6E1'SU9DW^YVY :KY) ZI?3%;1L
M/9FY[ N[T!G4 G *&GNE],=#>->:>09_$=U.X^XJKS'QG$[G);S)@I*J^LCT
M,(R'HS[KH#[MO*2.UAKZ>XH4=].VG;AN!US23I0F>&$9;=]G6K;1I7:9Y+/.
M="2V\0I1F>'N]\L(0Q[W*95RHW.E9!>5=8RAT>*'(:=4^D29"&8QAR6(\E_R
MR@XGX;(4=OAIWL.VWRYW.J0XK!E/@X3(,I''&'/K3NG8/I'26]RZTE8NGK6F
MSK"AIU*!U2\& Z()'$F9'AR3F>2<@8?597$Q.6F.J79N3)<VPO%O?;T^-4M:
MEE!ES)\AUHN=B%.)1OL-SJ\;*LFY-R[D-LKY"H:65^$%(Y:2 <R<<1C&%^IN
M^MB;7V__ '(DJ1;7&@HZU D!0PQD)8D03Z?FO&*3^;K;E2(F5S7G3$=[+&XE
M:F-'XXPQQ7EJ\(K&P@%#:6D%Q]&P6C;?Z>HU9?57>";1<V]JT+F@I2-4CXL.
MO[(S3T0_Q\N5YHWO5'<U2Q4W:H=YU,TWX6Q2JD4%39*B5R(FK4 >B+IP_P ;
M\%9]-F7MGE<G^7FRU,9A5RPTVXI2BI:7E+45L1$]R4[*!(.YWUF]+NAVM9_I
M2DN2XB?TQMM\V=4LN>9J0I!&,D^%/=C#?JX?]O3]8IJMJ*!2[%I;$9R3.0A+
M[R6^Y*8DI+J/.ZKH2=AUTV<N>ZV5<Q08Y,_P'^*.*)%%44ODZALE8)Q3A]<(
MGR)PP*ZUDQL2_CAQ:T_I+TIAWL[EJ:;,64I2=^]:>K>QV'QU8J#<S#+7,O )
M1*7@\/BX=.&<0=;MQ86?+I6$]9G]$5]KVD9^Q6_KME>X30DH\BZZ3:.RK(A0
MW ,>$R]XUE)]"-.F/4BV,+*0TOE_IU0C1;874*TOU++7;+ZX'61\(9OC]6Y:
M):8MJ]"P7'X*EJ=0R-P7E,K0A2>X'TVZ:F;7OBT7=N=.R\VO]8X?,(A:NEIJ
M*J#2ZAIQN?W3C\Y@<TV)6UV"[7UL^46U.AQ,6$Y*4%- K6A:&QW(4$CJ-2Z[
MDA+&LO-)=).!Z.'&%G:-LU$Z)MQ;&D8SGCQX=,;-WBN0U4:/,L\;O(,5PE+,
MB162V&2I)^HJ4ZP1Z?#<:*EK'GR)OL'L'VPM6A%+2I*670[J ,\I8]49>+>'
M4<X<H8YA3;ST:M+J[S,;!)2EFIPRJ47K69)4%#K)2R6&&P>YQUU/RZV!RD=#
M84AQ!/Z=<5:YW-ME,VVUZ^N"'[J^ J;#.9:1/&>++CT/(]34S,7QNMC.2)+%
MLPH5%I31FD*<4_8*F1PX]U :\I)TVY521-.F<-[?=&W*4NUT@YU8#Z8?_P!O
M_ 4/@RI_5[M,6?RI:P$(GRVTH<:P6"O8&GHY!&TBP<"@AZ2/K0=TC;UT88JP
M)JT]T0M9>*:IFT20)P:)49I2%K*25DJ5N22=SOL.N^X2.@WZ[>IWT4^!SB.
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MKE.(0&OX2H\8-*8;4YLIL%!W2'E$>FM5].[/34M4M^NT^10TI)D9G5,2D..
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MCL-M""@59O0OTK!D/)"62I6Z4^I2.FXV]#^.A B-Q%F.4DNI*TMJ[T[[$D[
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MV2=I"XT.'#R#&[1U788%K+3%G.+C.;%2'P$;[A.D=Q->13S49Z1%LM3]OKG
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M8;*$A/J?D-(KNUN2<%B1$XN=0S<%4Z?"<$@900*/&\C=6(3=-9RYK*0IUF)
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M ,8Z9MM7DC]<>_DJ^4]**/)XP^E_L 1W;D$ZM@HE?VR1_P#Z#YE1G"JY/_\
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M'%,PPE69PZXU,KX^R>OGY+ N^3JNAM)SDR(I-1C]M.5"#Z0J+_&4ZRX([:$
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M'J$H*9G\[W^/N,S:;^78=E$[D1;FSI(=TWLG9UD+BNE9W'H"G3C<O]JI9YM
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M5X][K:._1@K6<XWD*%U'ZX]D#4"DLJ*D;<3)364TFDDOH:\DM&Z76V6PLGJ
M-8-ZH>M-,[94O[;+Y6'T(5-&G$ZI_>.&&<6_:_H4/3^^*_N)JF=;(*4:5ZQX
MB)3FD2RC@][KK[DC+,\>5RYG.<WU+!F/LXYB]I?O6:ZAB.I+)?$9:6Z]#BXP
M'E=[ X#T'QU3[3OG<-XLHIZA>I? 3X9Q[W]/=C>GM!:_.T[')N:Q,E"!(F73
M.)7'_<'@^/<8NX*BA@,67Z$(T%MC^"RXIL/-.6\MN*VA<NW5Y4H275%OMW(
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MY'D&^P]3K2?C5_\ AQJ)H\T% 3U<#.>,ND"*8JCH?[W2)GDEA1]H4CZX-?\
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M=; EF-9V]O*:2U(2PH(?<CM-...2.]M'HKM'=IZF^H<1CF28S#SK>T732NR
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MYILMH0Z7'5/J6'GENJ5NXX1T&VPZ:]#>F-OIJ9E]RF<:4^V5 ZE2. &6&48
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M[.=#$:OKXL)#GV_:M6RG5E 1ZGIK4?37T7;O% ZI];!J@I7O+X82QD8H6_\
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M3A(B6>$/!A_#%]F5U5-U4:R5C,6<NX;E6;S5M:2;FR!^[?LK ,N+D(".U*$
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MS%4K4P<L9PJU<;@43:4099#YH)$WDO@OAG,<[>HJ]#^4(A4F0.1L?@H:QZ#
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M.0]YXEQ6OA3<IA9[DN)(2GLVU<;94(IJA+RC)N4N^(O=5QJKK9JIYY8*.2K
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M'$H(V!&H)]BFK5\U(()Z#%K:K'J"G":<B4N.,0&.9/6/P)\>U>+E/*;<*K$
M*BU[Y2K=-@% J#2S^10/J->D?3;>]GH-LNVB\);-0I) ,@#D1G$ 7W)\,X@.
M+:J986C./T46)8L7%DJ'"=<2E29C7<?&])6KN'B4G?8$'H-85?Z&CH[Z[4TN
MKD*DH3,\YDPJQ4.H>#@,@(U?<Q[;>9\<A2V^#;$6%(]!8BSL$=D-QXK]A(?7
M,G3*9UQI:C$DS/X"F@0D;DC;455:+DCDJQ$QEAE%\I-V/--ML)TR"TSPX#.%
MWXNPOGZSR*#AG(/%]-@F(6E5)_F!]N-%>:LK-E:8R*]7W ?ES43)"D=ZRM:
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M2$HE?;Y[M,GP>?E]A"IJV]5F<Z33V##BI59+ER::<##KG;2,^@Q*R*IK?9*
M702D]%:84/J)3V6@5;:@-JJ% R)2"<8S#U2]$ZGU'KF:VN?=%(PO4.4LMY=,
MIS$6CC%C++WEG'+=F,]67E_GU8\BL88\#)=F7$5[[:&VWV!J*QV_04_40"=^
MNLZKJQ^HJ5UKDN8K+#"7#"-+MUM336.GLE4M!I:<:!/WL.E7$QU4]X\6REO7
M<=VHE5$A$U<3QSHC+$F6Y'2T';&(ZF6HOPI#A/82-P-9-?+HZ*A]#H24EE8
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M)UIQPPQB!QKW.C$Z6'@60V%E3Y%5UD>/%C3X_P!Q$EHBM-L19$90 1)K'RT
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MIMT/KK;+'44']QLUE?(MR$Y"9Z\Y1XB]6*7=#'IB_M782%?'PH@*)*6Y8_?
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MKXV!J3YCED3GAFGC*'T][#*;+W"1:E;+RS(XZH A:7 &E+=L+U*FW&^TD[!
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MJEE\N\/\OX Q*QKAO%V)61Y;E8D%B\JVL>D*KX>$WV(N(<E@6#)$)PEA;3C
M"E* ZZG+[8S3*T@@IT Y],4;TBWLFZ*>H*@$*#RY3PPPZ8HO)[N$9;@5P:SE
M.EAV;%Q:2>.($..:+#W,>2XX]"PNPB,/S:ZLN*5U+K:%M>,N [J0G<ZS%]NG
M34%"AXA'KO9UT51H4VCW,\XY(9U@7("+"KM\AA.8V[)\\R).AMIG5]RRMPH
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M G6@B9B KJVDS-3%:BT55SV5>6DFHF(@6==8)0EME+$A9#+K4CHGPN[M.^A
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M!3/2:%,J#;MV#54(L1BY%O\ :M.V%L8\:)*>E,LL$I5W!2!\5;]*]=>>3R:
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MB0G?OW:.FL+.!9*3V":HPW&6R@#?9Q2U ]/V:@FVD-NEU'OJB8MX6E)<IA+
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K TZL651&0IQXR1)$@(2&RDJ4++\T19.X/[D&#?G>6>)E*:9XZ9YRX1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tv503751_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv503751_img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!1@(" P$1  (1 0,1 ?_$ /8    & P$! 0
M       $!08'" $#"0(*"P$!  $% 0$!              8! @,$!0<("1
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M#[V<NQ&I?#$O)[2?!QZ0RP NQ:B2I*)1D(4I8V(T16LYMROF?QE^Y?\ =O\
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MT>=S=+W&^!R'.28[<3DD*Q"F<3G\6)!_3HD?-O[HIO)6XU:Y[*&YQ>0EO8(
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M<GB#A23Y'95A-5ROD%&_P'1N+N,9J)+"J>YFYJ_A?Z!9S*Z4RVIAM4UZ2TI
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MMA%IZW&\_9DQ,HK[+'65HK+5,]B2HI==276R=AHBMTS'0$?,$]Q 2HI &X
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M_AHBTKF,(6E"E$%:"M.^P"MMAV)W4.]SYOW1N=$7LR&PGNV7Z@!/;LHJ)V"
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MT#M0>N^VB+W[R-NXD@;;@G8;]-R!UZD;:(M"I\5)(]PJ(_T$+63_ .Y"4DK
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M"NKR7(%.-39"?;1!:[>UQ9[M$3BY$^^?YH</WO/W!_(7'?C4.:<2\GO$SA'
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M);8SQG88[Q995,O!,=OI#DNZJ,6>B8^ARE@VDQQ3SS3)"%N*W(]=-%BDY9N
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MG6G6PE22I(3\PWW/1/3U&^BY=_;2TX].'M3ZYQQE[/O'/F?%T-ERP?XUL[B
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M"7L6OY"!VN*:4=X<L#V)C&RDJ[@H:+9:TL:&G:!3N3"?85[2O;2%#H3W?T]
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MR>X++6Q7OOND$C?<[[;[#55TU/E,\N6I:& "$)3MT._3][?KMJBP':EIY]M
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M.Q2=QK7M,#$UL@?Q%P)V_P"A2VYY[?@YO-8]_$)'UH_4"NX $>C55*R+%YF
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MB(ZD->=-.G8J?LUR1(6PX1W%P=W:=T=NVRNT_AO_ %ZCHE8P<+C[0T[E[/$
MV)HZ&CZ$F3Z-+!4B,Y\ZUJZ'IND]223^ ]!IX\?6MED3WL+V[ 4VHL5]J8][
MA)0D'U'0^H'Y$[?#51*QQX1M*T9IVQ AS7^AI*1[91*%-I2O91 5\I ">@)_
M/KK(L<<S9?=#AVBB4:A$>&T"S&"B "2I03W* &YV^/75%F5AN+0F3_>7?D[B
M0$GU&RNNW4';;50N?>>^WL^M.SGC'4Y;P5R[CR$*>$K K.4PA(W6J71;V[6W
MX )BD[C\-56*W<&3-<=GY%PAXK?66"IKU]IOHH]OKL@>OXJ0?ST7;C/B^XK
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M;E'11)'HL_$==$WKN5VG\/\ \4AV_'U_#5% O_&%S \U9<*3Y1<^0'$H:?\
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M!;<&XMI-Q$4[$8=?_CNU\6,N+[18#1#)47 ACM"P5 ZF-[S%9V=DZ_+Q7M4
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M8F1Y$EKN$#VME:*"[#'LTY3I\S:II!Q*YQ'&LBOWZV9<LS($N?2H:F,Q5Q'
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M'C,B*RKVVUS+,M0V(J2I("I"GG I(*3N2!T&K;S/6D#28C4]:W+#'Y.>3@N
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ME'W^9K#B_(JXVT^@L.38349V'34;5A9XO:U$I2?U-V\;L7$EJQD24#M0D@$
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M63KFWFMXHS.QHH2-2G=,SF\Y1J\EQG);LO\ ';L6NK[:FKY[U7)=E1'X\Q]
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MN\12$I<6Q[/S>XA0[NY)!WUT,_R%#D+-MWA7$$,H:D'VMM= %DQ^9E8#+D7
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M:*X)$EY];>Y=6VA*$I2-CL=X1S9<00V :UQ.F\J:_)'"W\G-ESDW1D217+1
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MWN">TJ4H>NO3XK2/#V!NK>IG&GM:CKTT^E0JWMLG(ZMR&!V^@.WO58<JQJ!
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M9YI\_!,!X?8?M77S^4L _P#GE+_ZJ+]"_?'_ )F_\N_VG_&?S_MU(?%9T?\
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M>2H%.X*03OKE<S<^9'"RG&R4/$[\T\6NS=L6OB?EWBL]:17K9"Z[EDTX_9W
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MJX:QWA#EZ!2OY!RO99MC[&,8U,QV@+EU;6\FO858+94RTE:681;47WG5AIM
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MK_F]=$I#+D&<J9"@0_W?;<COJ8?"O84E:%,M+)/=J5NB%M (V[:*,7S&2O\
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M3JN/;1SW+BZ6H*IC5KQ*NOX7(DC%LEL;.3&48]-;0?J:=2I)]L;K)^1CVP%
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M0$K4.OH-66K6BP>0!7BVTZ@MS+\P--FVS::$N&P[53[G'@_D#R@_4L:XDO\
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M+CF.AZM4A"O=#3C<)Y"_E5'9>="?F*5;+ZD^NVVN]-B[?%7)-JZ0CB/O$'Z
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M1[:4]?R'766;+YB[QC;4!N[:=RY5LV]<?\5P\'4:JNF0Y])1(8J\&IZ^QP2
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M<$RK$6,IQJ>X.U:>XMJEN=JE[?-L/SUTG6E[D8JAQ( T[%PIC)'<<3S[-?\
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MF0[7.([4HM\#</,B+[7&6#-?1R#*C]F.UP#+Y1V%UG^[@MK*?4CX:J&M;[H
M609"Y;H'.I3I1RTX7XNN68\:SP/%)L>+($MEF320G&420?E>0WV;)<2!T.A
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MW3\-:[+$M>"1IV(+N9AXFN-1UI!L>(^-;B4N=:X-C%A-6 E4R;30Y,A24#9
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M2DF=X\<'6Q";/B'CN?UZ*F8O6R%$#J"I3C!/=JO"T;AW*QN3NN+1[QZ4BO\
MB=XW2=DR.!^)WD@'_:X93J(].@[HBNAU3A9O:WN"S?$KO[[^]2)_A%QG_P"H
M&(?^8O\ AM_T)"_\Q/\ U._V/_FU_P#HO^R_U=*#H"Q>9E^\?>XMN_I[>M2/
MVC\]756.I0[!^)_K_P"#3B5>(K 0 =P3O^9U4N)%$+B11>]6JU>.P?BK^O\
MX-%=Q'J0[!^)_K_X-%8]H>:E9[!^)_K_ .#16^&.DK/;^9U6J< Z2AV_F=*I
MP#I*';^9TJG .DH=OYG2J< Z2AV_F=*IP#I*\]@_%7]?_!JO$LO$>I#L'XJ_
MK_X-.).(]2'8/Q/]?_!JG$G$5GM'YZ55*E9V_,Z55G".DH=OYG2JIP#I*';^
M9TJG .DH=OYG2J< Z2L=H_/2JR5*':/STJE2AVC\3I55XBL=@_%7]?\ P:HG
M&>I9[?S5_7JS@'252O8AV[_%7]>KV^RJ\78@$ ?$_P!?_!JM51QXA19[?S.E
M5CX!TE>>P?B?Z_\ @U14\,=)60D#XG15# -Y0[?S.JU50VAKJAVC\]*J^I6=
MOS.E59PCI*P4@_$_UZ55S?9V+'8/Q5_7_P &J\2NXCU+!;!^*OZ].(JO&>I>
MNW\SJE5B+:FNJSVC\]*JYOL[%CM'YZ50ZBBSV_F=*JS@'25CM'YZ560&@HAV
MC\3JAU5CF\1J4.T?B=5J@;PFNJ':/STJKZE#M'XG2JKQ% ) ^)_KTJK7>UM0
M[1^)TJJ <)JL=@_%7]?_  :HK^,]2'8G\_[/\FKN(K$6 FM2LA('XZI5. =)
M6=OS.E54-H:ZK.J*Y8V_,ZK56\(ZT.W\SI54X!TE#;\SI55#:&NJSJBN0T18
M(W_'14(JAV_F=5JK> =)0[?S.E4X!TE8[1^>E5D!H*+.P_\ RZIM5#KM0V'X
M:*E %CM'YZK575*SM_N;:I5*HLJ;'0OVROYAOOL"0G;MW[B.B?WQZZR"-YV*
MSB/W7=RR9<<;_P 0*('<0@*60/3?9 )U:6D&AT*JXEAHX&O8LHE,.#=*]Q^)
M2H?[H&J45O'U'N6SW4]!LK<C< ))Z?T;C2G8J\?4>Y9"TJ (W(/Y?AZ_U:45
M]$"L#UWTHK2YK30D(>XG\]**WC9TA#W$_GI1.-G2$.]/Y_U:HLE.L(=X_/\
MJT5#0;2%D*!Z=?ZM$J-Q7K1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T
M1#1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T1#1$
M-$0T1#1$-$6-Q^?]1U6BMXAUKPIQ*=M]^OY:M<X-VJG&.@]RQ[S?IN=QTVVZ
M]-6>(WK[E<305H5CWT?ZW]6GB-'3W*P25W.[EZ]U)].[^HZM\9O0[N636E:'
MN6/>1^"A_P"].GC-&YW<L9E:#0U"P7VP">O3X ;G^K56RM<X- .O2%D%#K4
M=:PF0A?[H7_\$]/VZS45?9W.8?2$/J&M]BK8[[;$$;?U_ :4*QF6(&A>VHZU
M@26COVJ[@#VDIZC?\.AWU4-+MBH)8W>ZX%>%SHS:RA:RE0 )W2KH#Z'T]-.
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M(AHB&B+65D$CIZ_]WQT18[S^7]O^71$.\_E_;_ET1#O/Y?V_Y=$0[S^7]O\
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M':%H;F'CE5=WDMT;^K3,2&2X!^1.M"[Y^Y=LBULT@)<*Z$%2BP^0'SGRSO\
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MW.X!!&J\(1UP*:.->U$E8\:]PMF.\74I2DR%SY3;R'7C\T8L!S=*@DCYU*2
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M=;:<DV4(K]1-I9J%)Z[?-V=R1M^TZJ?"A]FX<.,[*:+5FP.0LAPW3'.D(J.
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MQ/IN1UV'XZW.!W2KN!S1[+RO=-3O%,E^("\ZVO\ NJCO\S6VY5V>O;\-:QG
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MUIW&5NV1<302>Q2ZU^7V7G9K+'7]()MN^?6#-K[8>!YE(2TE00W*%? :1O\
MNJ23(4KKKG?'LA^[]2ZT?RBGN1^MN8P>T)C3ON 6KLA3=5Q6RVV%DM+N,B"
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M?YE?+?\ C(_Q#[4C.\<\B*3VIP'-=PK<_P#DO>^FWX_0Z?"\_P#NCW?D5?\
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MU_\ N1 W_P#D&GE[;]U'^$*O\P9S^+N/QN^U>3QY@_I_*E !OOM^DP!U_/\
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ME4\P9P[+N<?ZY0_D'""-CB>/$?A^DP=O_D.J^5M?W4?<%09_. U\W<?C*P,
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M#1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T1#1$-$0T1#1$3?["AP+* G97>5A)
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?M_2]GM]ORA&W:$[=-MNFB(YHB&B(:(AHB&B(:(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tv503751_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv503751_logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 3P#M P$1  (1 0,1 ?_$ (<   $$ P$! 0
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MD/AB8  > NC_ .SMZT%HOY5I=-L6+\J1@"63R51G#DRGH$ 44:.<8&8G])A
M1*4A/5X\>0\\!M=EZ-.VOK;%UDCJ>[$+[DV$@R%?.-:,X.D8UK:FC$3+JQ+&
M,FW\]AZQ.WI ^&0BS:OKCY\).2G](\"0_JB[_8O9[*JVE6[.,G6H._5:=N(!
MSCZR-)2OTW*$U&) 9XQIR-F,$M6+HNF45TX%XJX*\0\J1[MR7^$4+0D5*IOD
M_642^1 H^_W^0#QX_>' W@?T^_@' . < X!P#@' . < X!P#@' . < X!P#@
M' . <#723HK9 QA'QX#SY\?C^' IR_<.[KYWRQE?"'2_I%*K(;!;@*Q_]M=E
MBWKAHM1\.S2[DK>NOI%B;YF$C;'$1SZ7L*X!\1.ML?A@4Q7H\"<GK#ZRL!=;
MVO-<PEAB$;+R*J#*4RIE!XS1)<,N7D&Q22-GL+TA2KIQJ*PG3BHPIOE8MGZ4
MTP$XJ*J!*:TB6S4@ 4A $ \>PA?=^'O_ &<#/^72_P";^_VC[?ZA\^.!J7\*
MU=)'(*1/(E-^;Q[?/CV>/;P*Y?>KTV5?L$PXYRCB5@C2]Y,'Q?ZFP1E*"7/
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M)"QS"'AX=@TC(B(BVC>/C(N,CVZ;1C'QS!HFDU9,&35(J22212IIIE I0
M.!])!=9JP?.FS8SQRW9N5V[1/SZW2R*)U$FQ/ "/J64*!0]@^T>!4[^U/I58
MR7B7>#>^]N&MIVSV&W3RW7\N6:60*YMU3A*\6 LD9C_Z@Y SIA'.9:TN)!1!
M'T(J$^53, @U3*F%E7:+".*]D-><Q8.S5 1%EQCD?']EKULC9E!LLV18N(MP
M=*9;G= )&$K7W22;YD[*)5&;INFL0Q3D*8 @4^TQR-=;WU(5^!MTN^G8S#V?
M\T8FQY(/UC.% Q_$N:[9XN.1<&.<5F47*VMZBW](%221 J1  $_' XKKC_\
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M1JE4PY46MYOMBR)DM9^TI\)$5UW-P)7BDJ_CC-R@1<51743(0AQ-XX'#Z?\
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MDNX7".MFS\_I\KK[NGG[-U9QG6,NS\-J]K\IF5G#46W/7$9$RLBI&VF.D&9
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MP19%GY2F;(*G($HA1\AY_I$!_> B _@'XAP/> < \!^S@' . < X!P#@' .
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' < X!P/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
